# Agenda Item B

Consideration of Bills of Interest to the Board of Pharmacy

#### State of California

Department of Consumer Affairs

#### Memorandum

To:

Legislation & Regulation Committee

Date: April 14, 2006

From:

Jan E. Perez

Legislation and Regulation Coordinator

Subject:

Legislation Update

# **Board Sponsored Legislation**

# AB 595 (Negrete McLeod) Pharmacy: compounding of prescription drugs.

Status: Senate Floor.

This bill is sponsored by the board to establish standards for pharmacies that compound and to provide direction for regulations that will follow later this year. The board approved this legislative proposal at its January 2005 meeting.

# AB 2408 (Negrete McLeod) Pharmacists, pharmacies, and nonresident pharmacies.

This bill is sponsored by the board and would update the definition of a pharmacy, nonresident pharmacy, and the professional practice of pharmacy. The board approved draft legislation at its February 2006 meeting.

Status: Status: Assembly Business and Professions Committee - Hearing April 17, 2006.

# Omnibus Bill (Senate Business and Professions and Economic Development Committee). Note: This bill is not in print.

The board approved the following proposals for the omnibus legislation at prior board meeting:

B&P 4314 & 4315 Cite and Fine, Letter of Admonishment.

B&P 4162 Wholesalers Surety Bond Requirements.

B&P 4104 Licensed Employee, Theft, Impairment: Pharmacy Procedures.

B&P 4084 Adulterated or Counterfeit Drug or Dangerous Device.

B&P 4160 Wholesaler License.

B&P 4180-4182 and 4190-4192 Nonprofit or Free Clinics.

B&P 4127.1 Injectable Sterile Drug Products.

B&P 4073 Substitution of Generic Drug, Check off Box on Electronic Prescriptions.

# Board Sunset Extension Bill (Figueroa). Note: This bill is not in print.

This bill will extend the board's sunset date two years, from 2008 to 2010. The board's sunset report to the Legislature will be due September 2008.

### **Bills of Interest**

# AB 2583 (Nation) Dispensing prescription drugs and devices: refusal to dispense.

Status: Assembly Health Committee - Hearing April 18, 2006.

# AB 2743 (Matthews) Pharmacists: ancillary personnel.

Status: Assembly Business and Professions Committee.

# AB 2986 (Mullin) Controlled substances: prescription requirements.

Status: Assembly Public Safety Committee - Hearing April 18, 2006.

## SB 1366 (Aanestad) Controlled substances.

Status: Assembly Public Safety Committee - Hearing April 25, 2006.

## 2006 Watch Bills

# AB 1908 (Karnette) Medi-Cal: pharmacy reimbursement.

Status: Assembly Health Committee - Hearing April 25, 2006.

# AB 2057 (Cogdill) Controlled substances.

Status: Assembly Appropriations Committee.

# AB 2198 (Houston) Health care: controlled substances and dangerous drugs.

Status: Assembly Business and Professions Committee – Hearing April 17, 2006.

# AB 2308 (Plescia) Ambulatory surgical centers: licensure.

Status: Assembly Health Committee - Hearing April 18, 2006.

# AB 2373 (Plescia) Automated drug delivery system.

Status: Assembly Health - Hearing April 18, 2006.

# AB 2730 (Nation) Medi-Cal: contract drug list: advertising.

Status: Assembly Health Committee - Hearing April 18, 2006.

# AB 2856 (Hancock) Informed consent: prescription medication off-label use.

Status: Assembly Health Committee - Hearing April 18, 2006.

# AB 2877 (Frommer) Prescription drugs: importation: procurement.

Status: Assembly Health Committee - Hearing April 18, 2006.

# AB 2911 (Nunez) California Discount Prescription Drug Program.

Status: Assembly Health Committee - Hearing April 25, 2006.

# AJR 40 (Chan) Medicare Prescription Drugs.

Status: Assembly Floor.

### AJR 49 (Nation) Direct-To-Consumer Prescription Drug Advertisements

Status: Assembly Health Committee - Hearing May 2, 2006.

# SB 1305 (Figueroa) The Medical Waste Management Act.

Status: Senate Environmental Quality Committee - Hearing April 17, 2006.

# SB 1430 (Alquist) The Local Pandemic and Emergency Health Preparedness Act of 2006.

Status: Senate Floor.

# SB 1683 (Scott) Pharmaceutical information: clinical trial data.

Status: Senate Health Committee - Hearing April 19, 2006.

#### 2005 Watch Bills

# AB 651 (Berg) California Compassionate Choices Act.

Status: Senate Rules Committee.

# AB 21 (Levine) Pharmacists: contraceptive devices.

Status: Senate Health Committee - Hearing Cancelled.

# AB 71 (Chan) Pharmaceuticals: adverse drug reactions: Office of Ca. Drug Safety Watch.

Status: Senate Health Committee - Hearing Cancelled.

# AB 75 (Frommer) Pharmaceutical assistance program.

Status: Senate Health Committee - Hearing Cancelled.

### AB 225 (Negrete McLeod) Electronic prescription information.

Status: Senate Business, Professions, and Economic Development Committee - Hearing Cancelled.

#### AB 283 (Koretz) Pseudoephedrine: retail sale.

Status: Senate Business, Professions, and Economic Development Committee - Hearing Cancelled.

## AB 657 (Karnette) Pharmacies: prescription containers.

Status: Senate Business, Professions, and Economic Development Committee - Hearing Cancelled.

### SB 380 (Alquist) Drugs: adverse event reporting.

Status: Assembly Floor, failed passage. Reconsideration granted.

#### SB 592 (Aanestad) Acute care hospitals: inpatient pharmacy technician services.

Assembly Health Committee - Failed passage in committee. Reconsideration granted.

# Board Sponsored

Legislation

# AMENDED IN SENATE MAY 26, 2005 AMENDED IN ASSEMBLY APRIL 18, 2005 AMENDED IN ASSEMBLY MARCH 29, 2005

CALIFORNIA LEGISLATURE—2005-06 REGULAR SESSION

#### ASSEMBLY BILL

No. 595

#### **Introduced by Assembly Member Negrete McLeod**

February 17, 2005

An act to amend Section 4051 of, to add Section 4019.5 to, to repeal Section 4033 of, and to repeal and add Section 4123 of, the Business and Professions Code, relating to pharmacy.

#### LEGISLATIVE COUNSEL'S DIGEST

AB 595, as amended, Negrete McLeod. Pharmacy: compounding of prescription drugs.

Existing law, the Pharmacy Law, provides for the licensing and regulation by the California State Board of Pharmacy of pharmacists, pharmacies, and other related practices and makes a violation of that law a crime. The Pharmacy Law defines various terms for its purposes, including "manufacturer."

This bill would delete the definition of manufacturer. The bill would define compounding of a prescription drug for the purposes of the Pharmacy Law and would make other related changes in that regard. Because the bill would specify requirements for compounded drug products under the Pharmacy Law, it would impose a state-mandated local program.

The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state.

 $AB 595 \qquad -2 -$ 

Statutory provisions establish procedures for making that reimbursement.

This bill would provide that no reimbursement is required by this act for a specified reason.

Vote: majority. Appropriation: no. Fiscal committee: yes. State-mandated local program: yes.

The people of the State of California do enact as follows:

- SECTION 1. Section 4019.5 is added to the Business and Professions Code, to read:
- 3 4019.5. (a) "Compounding" means any of the following 4 activities occurring in a pharmacy pursuant to a prescription:
- 5 (1) Altering the dosage form or delivery system of a drug.
  - (2) Altering the strength of a drug.

6

8

12 13

18

19

20

21

22

23

24

25

27

- 7 (3) Combining components or active ingredients.
  - (4) Preparing a drug product from bulk chemicals.
- 9 (b) "Compounding" shall not include the reconstitution of a 10 drug pursuant to the manufacturer's direction for oral, rectal, or 11 topical administration.
  - (c) This section shall not apply to over-the-counter drugs or nonprescription drugs.
- SEC. 2. Section 4033 of the Business and Professions Code is repealed.
- SEC. 3. Section 4051 of the Business and Professions Code is amended to read:
  - 4051. (a) Except as otherwise provided in this chapter, it is unlawful for any person to compound, furnish, sell, or dispense any dangerous drug or dangerous device, or to dispense or compound any prescription pursuant to Section 4040 of a prescriber unless he or she is a pharmacist under this chapter.
  - (b) Notwithstanding any other law, a pharmacist may authorize the initiation of a prescription, pursuant to Section 4052, and otherwise provide clinical advice or information or patient consultation if all of the following conditions are met:
  - (1) The clinical advice or information or patient consultation is provided to a health care professional or to a patient.
- 29 (2) The pharmacist has access to prescription, patient profile, 30 or other relevant medical information for purposes of patient and 31 clinical consultation and advice.

-3- AB 595

(3) Access to the information described in paragraph (2) is secure from unauthorized access and use.

SEC. 4. Section 4123 of the Business and Professions Code is repealed.

1 2

- 5 SEC. 5. Section 4123 is added to the Business and 6 Professions Code, to read:
  - 4123. (a) A compounded drug product shall only be dispensed or furnished to a patient pursuant to a prescription meeting the requirements of Section 4040.
  - (b) A compounded drug product shall only be dispensed or furnished to a patient where the prescription has been generated solely within an established professional relationship between the prescriber, patient, and dispensing pharmacy.
  - (c) A pharmacy may conduct anticipatory compounding of a drug product in limited quantity, as defined by regulation of the board, before receipt of a prescription order for that drug product, where the quantity of each drug product compounded in anticipation of receipt of prescription orders is based on a documented history of receipt of prescription orders generated solely within an established professional relationship between prescribers, patients of the pharmacy, and the pharmacy.
  - (d) A pharmacy may contract with another pharmacy to compound drug products on behalf of its patients.
  - (e) A pharmacy may only base its anticipatory compounding on a documented history of prescription orders received for its own patients or customers, and not those patients or customers of pharmacies with which it has a contractual relationship.
  - (f) Notwithstanding any other provision of this chapter, a pharmacist may do both of the following:
  - (1) Compound a drug product pursuant to a prescription, for delivery to another pharmacy pursuant to a contract for the purpose of dispensing or furnishing the drug product to the patient named in the prescription, provided that the drug is not compounded prior to the receipt of the prescription.
- 35 (2) Repackage a drug previously dispensed to the patient at the request of the patient or the patient's agent.
- 37 (g) This section shall not apply to over-the-counter drugs or nonprescription drugs.
  - SEC. 6. No reimbursement is required by this act pursuant to Section 6 of Article XIII B of the California Constitution because

AB 595 —4—

- 1 the only costs that may be incurred by a local agency or school
- 2 district will be incurred because this act creates a new crime or
- 3 infraction, eliminates a crime or infraction, or changes the
- 4 penalty for a crime or infraction, within the meaning of Section
- 5 17556 of the Government Code, or changes the definition of a
- 6 crime within the meaning of Section 6 of Article XIII B of the
- 7 California Constitution.

#### AMENDED IN ASSEMBLY MARCH 27, 2006

CALIFORNIA LEGISLATURE—2005-06 REGULAR SESSION

#### ASSEMBLY BILL

No. 2408

#### Introduced by Assembly Member Calderon Negrete McLeod

February 23, 2006

An act to amend Section 10153.4 of, to amend, repeal, and add Sections 10156.6, 10156.7, and 10215 of, to add and repeal Section 10153.10 of, and to repeal Section 10154 of, the Business and Professions Code, relating to real estate salespersons. An act to amend Sections 4036, 4037, 4050, 4051, 4052, 4112, 4120, 4201, 4207, 4301, and 4306.5 of, to amend, renumber, and add Section 4052.1 of, to add Sections 4052.2 and 4052.3 to, and to repeal and add Section 4302 of, the Business and Professions Code, relating to pharmacies.

#### LEGISLATIVE COUNSEL'S DIGEST

AB 2408, as amended, Calderon Negrete McLeod. Real estate salespersons: conditional licensure. Pharmacies.

Existing law, the Pharmacy Law, provides for the licensing and regulation of pharmacists and pharmacies by the Board of Pharmacy in the Department of Consumer Affairs. A violation of the Pharmacy Law is a crime.

Existing law defines a pharmacist and a pharmacy, requires pharmacists and pharmacies to be licensed by the board, and authorizes a licensee to engage in certain activities. Existing law also sets forth activities that constitute unprofessional conduct for a pharmacist to engage in.

This bill would require a pharmacist to be a natural person, and would entitle a licensed pharmacist to practice pharmacy within or outside of a licensed pharmacy. The bill would revise the activities in

which a pharmacist may engage, including the adjustment of prescriptions and provisions of cognitive services, would revise the pharmacist's responsibilities and requirements with regard to certain activities, and would make certain additional acts or omissions unprofessional conduct. The bill would revise the definition of a pharmacy to include, among other things, all pharmacies in which the profession of pharmacy is practiced. The bill would list different types of pharmacies and would require a pharmacy or nonresident pharmacy to specify its type in its application for licensure and to update the board if that information changes. The bill would make it unlawful for an unlicensed person to perform any prescription review, consultation. drug utilization review. medication management, or other cognitive services for, pertaining to, or at the request of, patients, prescribers, or other health care providers.

Existing law defines a nonresident pharmacy and requires a nonresident pharmacy to meet certain criteria, including registration with the board. Existing law prohibits an unregistered nonresident pharmacy from engaging in certain activities, including selling or distributing dangerous drugs or dangerous devices in this state through any person or media other than a licensed wholesaler. Existing law requires a nonresident pharmacy to disclose to the board the location, names, and titles of specified persons, including all pharmacists dispensing controlled substances, dangerous drugs, or dangerous devices to residents of California. Existing law authorizes the board to deny, revoke, or suspend a nonresident registration for failure to comply with specified requirements or for conduct that causes serious bodily or psychological injury to a California resident, in specified circumstances.

This bill would revise the definition of a nonresident pharmacy to require shipping, mailing, or delivering directly to patients in California, and to include a pharmacy located outside of the state that performs prescription review, patient consultation, drug utilization review, medication therapy management, or other cognitive pharmacy services for patients in this state. The bill would delete the requirement that a nonresident pharmacy must disclose the location, names, and titles of pharmacists, and the prohibition against a nonresident pharmacy selling or distributing dangerous drugs or devices in California through any person or media other than a licensed wholesaler. This bill would also delete the authorization for the board to deny, revoke, or suspend a nonresident registration for

-3- AB 2408

failure to comply with specified requirements or for conduct causing serious bodily harm or psychological injury to a California resident, and would instead authorize the board to deny, revoke, or suspend a nonresident pharmacy registration, issue a citation or letter of admonishment, or take any other action against a nonresident pharmacy that it may take against a resident pharmacy. The bill would also authorize the board to report violations of laws or regulations by a nonresident pharmacy to its regulatory or licensing agency.

This bill would revise and recast related provisions of the Pharmacy Law.

Because this bill would create new requirements and prohibitions under the Pharmacy Law, the violation of which would be a crime, it would impose a state-mandated local program.

The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.

This bill would provide that no reimbursement is required by this act for a specified reason.

Existing law, the Real Estate Law, provides for the licensure and regulation of real estate salespersons by the Department of Real Estate. Under that law, an applicant for licensure as a real estate salesperson is required to submit to the Real Estate Commissioner evidence of the successful completion of specified courses in real estate either prior to issuance of the license or within 18 months after its issuance.

This bill would, for persons who apply for licensure on or after January 1, 2007, delete the provisions from the Real Estate Law that allow an applicant to submit evidence of his or her completion of the real estate courses within 18 months after issuance of the license.

Vote: majority. Appropriation: no. Fiscal committee: yes. State-mandated local program: no-yes.

*The people of the State of California do enact as follows:* 

- 1 SECTION 1. Section 4036 of the Business and Professions
- 2 Code is amended to read:
- 3 4036. "Pharmacist" means a natural person to whom a
- license has been issued by the board, under Section 4200, except

AB 2408 — 4 —

as specifically provided otherwise in this chapter. The holder of an unexpired and active pharmacist license issued by the board is entitled to practice pharmacy as defined by this chapter, within or outside of a licensed pharmacy as authorized by this chapter.

- 5 SEC. 2. Section 4037 of the Business and Professions Code is 6 amended to read:
  - 4037. (a) "Pharmacy" means an area, place, or premises licensed by the board in which the profession of pharmacy is practiced—and—where prescriptions are compounded. Only a "dispensing pharmacy," as defined in subdivision (b), may possess, prepare, manufacture, derive, compound, repackage, furnish, sell, or dispense controlled substances, dangerous drugs, or dangerous devices. In all other respects, whenever the term "pharmacy" is used in this chapter, it shall be deemed to refer to all of the types of pharmacies listed in subdivision (b). "Pharmacy"
- 17 (b) "Pharmacy" includes, but is not limited to, any all of the 18 following:
  - (1) A "dispensing pharmacy," which is any area, place, or premises described in a license issued by the board wherein controlled substances, dangerous drugs, or dangerous devices are stored, possessed, prepared, manufactured, derived, compounded, or repackaged, and from which the controlled substances, dangerous drugs, or dangerous devices are furnished, sold, or dispensed at retail.

<del>(b)</del>

7

9

10

11

12

14 15

16

19

20

21

22

23

24

25

26

27

28

29

30

31

- (2) A "prescription processing pharmacy," which is any area, place, or premises described in a license issued by the board wherein personnel licensed by the board engage in or supervise drug order or prescription review by performing functions including, but not limited to, data entry, drug utilization review, patient or prescriber contact, patient profile review, and allergy and drug-interaction review.
- 34 (3) An "advice/clinical center pharmacy," which is any area, 35 place, or premises described in a license issued by the board 36 wherein personnel licensed by the board provide cognitive 37 pharmacy services including, but not limited to, clinical advice 38 or information, telephonic or in-person patient consultation, 39 drug utilization review, and medication therapy management.

\_\_5\_\_ AB 2408

(c) "Pharmacy" shall not include any area in a facility licensed by the State Department of Health Services where floor supplies, ward supplies, operating room supplies, or emergency room supplies of dangerous drugs or dangerous devices are stored or possessed solely for treatment of patients registered for treatment in the facility or for treatment of patients receiving emergency care in the facility.

- (d) "Pharmacy" shall not include a clinic licensed under Section 4180 or Section 4190.
- 10 SEC. 3. Section 4050 of the Business and Professions Code is 11 amended to read:
  - 4050. (a) In recognition of and consistent with the decisions of the appellate courts of this state, the Legislature hereby declares the practice of pharmacy to be a profession.
  - (b) Pharmacy practice is a dynamic patient-oriented health service that applies a scientific body of knowledge to improve and promote patient health by means of appropriate drug use, drug-related therapy, and communication for clinical and consultative purposes. Pharmacy practice is continually evolving to include more sophisticated and comprehensive patient care activities.
  - SEC. 4. Section 4051 of the Business and Professions Code is amended to read:
  - 4051. (a) The holder of an unexpired and active pharmacist license issued by the board is vested with the authority and responsibility to perform the following functions inherent to pharmacy practice:
  - (1) Interpreting, verifying, and implementing drug orders and prescriptions.
- 30 (2) Dispensing pursuant to legitimate drug orders and 31 prescriptions.
  - (3) Ensuring proper drug storage, documentation, inventory, labeling, and record-keeping.
  - (4) Maintaining accurate, complete, and confidential patient profiles and records.
  - (5) Supervising pharmacy technicians and other ancillary personnel in the pharmacy.
- *(6) Designing and implementing quality assurance procedures* 39 *and protocols.*

AB 2408 — 6 —

- 1 (7) Compounding drug products pursuant to prescription and 2 for prescriber office use.
- 3 (8) Maintaining safe, secure, and sanitary conditions in 4 licensed premises.
  - (9) Performing cognitive services, including drug utilization reviews and management, medication therapy reviews and management, and patient counseling and consultation.
  - (10) Collaborating with prescribers and other health care providers regarding patient care.
  - (11) Implementing standardized procedures and protocols regarding patient care.
  - (12) Administering or furnishing drugs or biologicals, where permitted by law.
  - (13) Initiating, adjusting, or implementing patient drug regimens where permitted by law.
    - (14) Any other pharmacy functions authorized by this chapter.
  - (b) Except as otherwise provided in this chapter, it is unlawful for any person to manufacture, compound, furnish, sell, or dispense any dangerous drug or dangerous device, or to dispense or compound any prescription pursuant to Section 4040 of a prescriber unless he or she is a pharmacist *licensed* under this chapter.

<del>(b)</del>

- (c) Except as otherwise provided in this chapter, it is unlawful for any person to perform any prescription review, consultation, drug utilization review, medication therapy management, or other cognitive services for, pertaining to, or at the request of, patients, prescribers, or other care providers in this state, unless he or she is a pharmacist licensed under this chapter.
- (d) Notwithstanding any other law, a pharmacist *licensed* under this chapter may authorize the initiation or adjustment of a prescription, pursuant to Section 4052, and otherwise provide cognitive services, clinical advice or information, or patient consultation if all of the following conditions are met:
- (1) The *cognitive service*, clinical advice, or information or patient consultation is provided to a health care professional or to a patient.
- (2) The pharmacist has access to prescription *records*, patient profile profiles, or other relevant medical information for purposes of *cognitive services*, patient and clinical consultation,

\_\_7\_\_ AB 2408

and advice, and appropriately reviews that information before performing any of these functions.

(3) Access to the information described in paragraph (2) is secure from unauthorized access and use.

3

34 35

36 37

- 5 (4) The pharmacist authorizing initiation or adjustment of a 6 prescription, or cognitive services such as clinical advice, information, or patient consultation, sets forth a complete log and description of all patient records and other patient-specific 9 information, including any test results or other pertinent data, 10 used, consulted, or relied on by the pharmacist during the 11 performance of the function. The board may by regulation 12 further define the required content of the log and description. 13 This log and description shall be maintained in a readily 14 retrievable form, and provided to the board upon request, for a period of at least three years from the date of performance of the 15 The underlying patient records 17 patient-specific information used, consulted, or relied on by the 18 pharmacist during the performance of the function may be 19 maintained elsewhere and not kept with the log and description, 20 as long as those records and that information are readily 21 retrievable and provided to the board upon request for a period 22 of at least three years from the date of performance of the 23 function. Otherwise, a duplicate copy of the patient records and patient-specific information used, consulted or relied on shall 24 become part of the records maintained. Where the function to 25 26 which the log and description pertains is performed on the 27 premises of a licensed pharmacy, the obligation to keep and 28 maintain the foregoing records extends to the pharmacy and its 29 pharmacist-in-charge, and to the pharmacist performing the function. Where the function to which the log and description 30 pertains is performed outside of the premises of a licensed 31 pharmacy, the obligation to keep and maintain the foregoing 32 33 records extends only to the performing pharmacist.
  - SEC. 5. Section 4052 of the Business and Professions Code is amended to read:
  - 4052. (a) Notwithstanding any other provision of law, a pharmacist may:
- 38 (1) Furnish a reasonable quantity of compounded medication drug product to a prescriber for office use by the prescriber.
  - (2) Transmit a valid prescription to another pharmacist.

AB 2408 — 8 —

- 1 (3) Administer, orally or topically, drugs and biologicals 2 pursuant to a prescriber's order.
  - (4) Perform—the following procedures or functions in a licensed health care facility—in accordance with policies, procedures, or protocols developed by health professionals, including physicians, pharmacists, and registered nurses, with the concurrence of the facility administrator:
  - (A) Ordering or performing routine drug therapy-related patient assessment procedures including temperature, pulse, and respiration.
    - (B) Ordering drug therapy-related laboratory tests.
  - (C) Administering drugs and biologicals by injection pursuant to a prescriber's order (the administration of immunizations under the supervision of a prescriber may also be performed outside of a licensed health care facility).
  - (D) Initiating or adjusting the drug regimen of a patient pursuant to an order or authorization made by the patient's prescriber and in accordance with the policies, procedures, or protocols of the licensed health care facility. as authorized by Section 4052.1.
  - (5) (A)—Perform the following procedures or functions as part of the care provided by a health care facility, a licensed home health agency, a licensed clinic in which there is a physician oversight, a provider who contracts with a licensed health care service plan with regard to the care or services provided to the enrollees of that health care service plan, or a physician, in accordance, as applicable, with policies, procedures, or protocols of that facility, the home health agency, the licensed clinic, the health care service plan, or that physician, in accordance with subparagraph (C):
  - (i) Ordering or performing routine drug therapy-related patient assessment procedures including temperature, pulse, and respiration.
    - (ii) Ordering drug therapy-related laboratory tests.
  - (iii) Administering drugs and biologicals by injection pursuant to a prescriber's order (the administration of immunizations under the supervision of a prescriber may also be performed outside of a licensed health care facility).
  - (iv) Initiating or adjusting the drug regimen of a patient pursuant to a specific written order or authorization made by the

-9- AB 2408

individual patient's treating prescriber, and in accordance with the policies, procedures, or protocols of the health care facility, home health agency, licensed clinic, health care service plan, or physician. Adjusting the drug regimen does not include substituting or selecting a different drug, except as authorized by the protocol. The pharmacist shall provide written notification to the patient's treating prescriber, or enter the appropriate information in an electronic patient record system shared by the prescriber, of any drug regimen initiated pursuant to this clause within 24 hours.

(B) A patient's treating prescriber may prohibit, by written instruction, any adjustment or change in the patient's drug regimen by the pharmacist.

- (C) The policies, procedures, or protocols referred to in this paragraph shall be developed by health care professionals, including physicians, pharmacists, and registered nurses, and, at a minimum, meet all of the following requirements:
- (i) Require that the pharmacist function as part of a multidisciplinary group that includes physicians and direct care registered nurses. The multidisciplinary group shall determine the appropriate participation of the pharmacist and the direct care registered nurse.
- (ii) Require that the medical records of the patient be available to both the patient's treating prescriber and the pharmacist.
- (iii) Require that the procedures to be performed by the pharmacist relate to a condition for which the patient has first been seen by a physician.
- (iv) Except for procedures or functions provided by a health care facility, a licensed clinic in which there is physician oversight, or a provider who contracts with a licensed health care plan with regard to the care or services provided to the enrollees of that health care service plan, require the procedures to be performed in accordance with a written, patient-specific protocol approved by the treating or supervising physician. Any change, adjustment, or modification of an approved preexisting treatment or drug therapy shall be provided in writing to the treating or supervising physician within 24 hours. as authorized by Section 4052.2.

**— 10 — AB 2408** 

1

2

3

4

5

6

7

8

9

11

12

13 14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33 34

35

36

37

38

39

40

(6) Manufacture, measure, fit to the patient, or sell and repair dangerous devices or furnish instructions to the patient or the patient's representative concerning the use of those devices.

- (7) Provide cognitive services such as drug utilization review, medication therapy management, consultation to patients, and professional information, including clinical or pharmacological information, advice, or consultation to other health care professionals.
- (8) (A) Furnish emergency contraception drug therapy in 10 accordance with either of the following: as authorized by Section 4052.3.
  - (i) Standardized procedures or protocols developed by the pharmacist and an authorized prescriber who is acting within his or her scope of practice.
  - (ii) Standardized procedures or protocols developed and approved by both the board and the Medical Board of California in consultation with the American College of Obstetricians and Gynecologists, the California Pharmacist Association, and other appropriate entities. Both the board and the Medical Board of California shall have authority to ensure compliance with this clause, and both boards are specifically charged with the enforcement of this provision with respect to their respective licensees. Nothing in this clause shall be construed to expand the authority of a pharmacist to prescribe any prescription medication.
  - (B) Prior to performing a procedure authorized under this paragraph, a pharmacist shall complete a training program on emergency contraception that consists of at least one hour of approved continuing education on emergency contraception drug therapy.
  - (C) A pharmacist, pharmacist's employer, or pharmacist's agent may not directly charge a patient separate consultation fee for emergency contraception drug therapy services initiated pursuant to this paragraph, but may charge an administrative fee not to exceed ten dollars (\$10) above the retail cost of the drug. Upon an oral, telephonic, electronic, or written request from a patient or customer, a pharmacist or pharmacist's employee shall disclose the total retail price that a consumer would pay for emergency contraception drug therapy. As used in this subparagraph, total retail price includes providing the consumer

—11— AB 2408

with specific information regarding the price of the emergency contraception drugs and the price of the administrative fee charged. This limitation is not intended to interfere with other contractually agreed-upon terms between a pharmacist, a pharmacist's employer, or a pharmacist's agent, and a health care service plan or insurer. Patients who are insured or covered and receive a pharmacy benefit that covers the cost of emergency contraception shall not be required to pay an administrative fee. These patients shall be required to pay copayments pursuant to the terms and conditions of their coverage. The provisions of this subparagraph shall cease to be operative for dedicated emergency contraception drugs when these drugs are reclassified as over-the-counter products by the federal Food and Drug Administration.

(D) A pharmacist may not require a patient to provide individually identifiable medical information that is not specified in Section 1707.1 of Title 16 of the California Code of Regulations before initiating emergency contraception drug therapy pursuant to this paragraph.

- (b) (1) Prior to performing any procedure authorized by paragraph (4) of subdivision (a), a pharmacist shall have received appropriate training as prescribed in the policies and procedures of the licensed health care facility.
- (2) Prior to performing any procedure authorized by paragraph (5) of subdivision (a), a pharmacist shall have either (A) successfully completed clinical residency training or (B) demonstrated clinical experience in direct patient care delivery.
- (3) For each emergency contraception drug therapy initiated pursuant to paragraph (8) of subdivision (a), the pharmacist shall provide the recipient of the emergency contraception drugs with a standardized factsheet that includes, but is not limited to, the indications for use of the drug, the appropriate method for using the drug, the need for medical followup, and other appropriate information. The board shall develop this form in consultation with the State Department of Health Services, the American College of Obstetricians and Gynecologists, the California Pharmacists Association, and other health care organizations. The provisions of this section do not preclude the use of existing publications developed by nationally recognized medical organizations.

- 1
- 2 (9) Administer immunizations pursuant to a protocol with a 3 prescriber.
  - (b) A pharmacist who is authorized to issue an order to initiate or adjust a controlled substance therapy pursuant to this section shall personally register with the federal Drug Enforcement Administration.
- 8 (<del>d)</del>

5

- 9 (c) Nothing in this section shall affect the requirements of 10 existing law relating to maintaining the confidentiality of medical 11 records.
- 12 <del>(c)</del>

15

16

- 13 (d) Nothing in this section shall affect the requirements of 14 existing law relating to the licensing of a health care facility.
  - SEC. 6. Section 4052.1 of the Business and Professions Code is amended and renumbered to read:

#### 4052.1.

- 17 18 4052.4. Notwithstanding Section 2038 or any other provision of law, a pharmacist may perform skin puncture in the course of 19 20 performing routine patient assessment procedures or in the 21 course of performing any procedure authorized under Section 22 1206.5. For purposes of this section, "routine patient assessment 23 procedures" means: (a) procedures that a patient could, with or 24 without a prescription, perform for himself or herself, or (b) 25 clinical laboratory tests that are classified as waived pursuant to the federal Clinical Laboratory Improvement Amendments of 26 27 1988 (42 U.S.C. Sec. 263a) and the regulations adopted thereunder by the federal Health Care Financing Administration, 28 29 as authorized by paragraph (11) of subdivision (a) of Section 30 1206.5. A pharmacist performing these functions shall report the 31 results obtained from a test to the patient and any physician 32 designated by the patient. Any pharmacist who performs the service authorized by this section shall not be in violation of 33 34 Section 2052.
- 35 SEC. 7. Section 4052.1 is added to the Business and 36 Professions Code, to read:
- 37 4052.1. (a) Notwithstanding any other provision of law, a 38 pharmacist may perform the following procedures or functions in 39 a licensed health care facility in accordance with policies. procedures, or protocols developed by health professionals,

**— 13 — AB 2408** 

including physicians, pharmacists, and registered nurses, with the concurrence of the facility administrator:

- (1) Ordering or performing routine drug therapy-related patient assessment procedures including temperature, pulse, and respiration.
  - (2) Ordering drug therapy-related laboratory tests.

3

5

6

7

9

11

13

14 15

16

17

19

20 21

22

23 24

25

26

27

28 29

30

31 32

33

34 35

36

37

38

- (3) Administering drugs and biologicals by injection pursuant to a prescriber's order.
- (4) Initiating or adjusting the drug regimen of a patient 10 pursuant to an order or authorization made by the patient's prescriber and in accordance with the policies, procedures, or protocols of the licensed health care facility. 12
  - (b) Prior to performing any procedure authorized by this section, a pharmacist shall have received appropriate training as prescribed in the policies and procedures of the licensed health care facility.
- Section 4052.2 is added to the Business and SEC. 8. 18 *Professions Code, to read:* 
  - 4052.2. (a) Notwithstanding any other provision of law, a pharmacist may perform the following procedures or functions as part of the care provided by a health care facility, a licensed home health agency, a licensed clinic in which there is a physician oversight, a provider who contracts with a licensed health care service plan with regard to the care or services provided to the enrollees of that health care service plan, or a physician, in accordance with the policies, procedures, or protocols of that facility, home health agency, licensed clinic, health care service plan, or physician, and in accordance with *subdivision (c):*
  - (1) Ordering or performing routine drug therapy-related patient assessment procedures including temperature, pulse, and respiration.
    - (2) Ordering drug therapy-related laboratory tests.
  - (3) Administering drugs and biologicals by injection pursuant to a prescriber's order.
  - (4) Initiating or adjusting the drug regimen of a patient pursuant to a specific written order or authorization made by the individual patient's treating prescriber, and in accordance with the policies, procedures, or protocols of the health care facility, home health agency, licensed clinic, health care service plan, or

**AB 2408** 

- physician. Adjusting the drug regimen does not include substituting or selecting a different drug, except as authorized by the protocol. The pharmacist shall provide written notification to the patient's treating prescriber, or enter the appropriate information in an electronic patient record system shared by the prescriber, of any drug regimen initiated pursuant to this paragraph within 24 hours.
  - (b) A patient's treating prescriber may prohibit, by written instruction, any adjustment or change in the patient's drug regimen by the pharmacist.
- (c) The policies, procedures, or protocols referred to in this subdivision shall be developed by health care professionals, including physicians, pharmacists, and registered nurses, and shall, at a minimum, do all of the following:
- (1) Require that the pharmacist function as part of a multidisciplinary group that includes physicians and direct care registered nurses. The multidisciplinary group shall determine the appropriate participation of the pharmacist and the direct care registered nurse.
- (2) Require that the medical records of the patient be available to both the patient's treating prescriber and the pharmacist.
- 23 (3) Require that the procedures to be performed by the 24 pharmacist relate to a condition for which the patient has first 25 been seen by a physician.
  - (4) Except for procedures or functions provided by a health care facility, a licensed clinic in which there is physician oversight, or a provider who contracts with a licensed health care plan with regard to the care or services provided to the enrollees of that health care service plan, require the procedures to be performed in accordance with a written, patient-specific protocol approved by the treating or supervising physician. Any change, adjustment, or modification of an approved preexisting treatment or drug therapy shall be provided in writing to the treating or supervising physician within 24 hours.
- *(d)* Prior to performing any procedure authorized by this section, a pharmacist shall have either:
  - (1) Successfully completed clinical residency training.
- 39 (2) Demonstrated clinical experience in direct patient care 40 delivery.

—15— AB 2408

SEC. 9. Section 4052.3 is added to the Business and Professions Code, to read:

4052.3. (a) Notwithstanding any other provision of law, a pharmacist may furnish emergency contraception drug therapy in accordance with either of the following:

(1) Standardized procedures or protocols developed by the pharmacist and an authorized prescriber who is acting within his

or her scope of practice.

- (2) Standardized procedures or protocols developed and approved by both the board and the Medical Board of California in consultation with the American College of Obstetricians and Gynecologists, the California Pharmacist Association, and other appropriate entities. Both the board and the Medical Board of California shall have authority to ensure compliance with this clause, and both boards are specifically charged with the enforcement of this provision with respect to their respective licensees. Nothing in this clause shall be construed to expand the authority of a pharmacist to prescribe any prescription medication.
- (b) Prior to performing a procedure authorized under this paragraph, a pharmacist shall complete a training program on emergency contraception that consists of at least one hour of approved continuing education on emergency contraception drug therapy.
- (c) A pharmacist, pharmacist's employer, or pharmacist's agent may not directly charge a patient a separate consultation fee for emergency contraception drug therapy services initiated pursuant to this paragraph, but may charge an administrative fee not to exceed ten dollars (\$10) above the retail cost of the drug. Upon an oral, telephonic, electronic, or written request from a patient or customer, a pharmacist or pharmacist's employee 32. shall disclose the total retail price that a consumer would pay for emergency contraception drug therapy. As used in this subparagraph, total retail price includes providing the consumer with specific information regarding the price of the emergency contraception drugs and the price of the administrative fee charged. This limitation is not intended to interfere with other contractually agreed-upon terms between a pharmacist, a pharmacist's employer, or a pharmacist's agent, and a health care service plan or insurer. Patients who are insured or covered

**AB 2408 — 16 —** 

and receive a pharmacy benefit that covers the cost of emergency contraception shall not be required to pay an administrative fee. These patients shall be required to pay copayments pursuant to 3

- the terms and conditions of their coverage. The provisions of this
- 5 subparagraph shall cease to be operative for dedicated emergency contraception drugs when these drugs are reclassified
- 7 as over-the-counter products by the federal Food and Drug
- 8 Administration.

9

11

27

28

29

30 31

32

33 34

- (d) A pharmacist may not require a patient to provide individually identifiable medical information that is not specified 10 in Section 1707.1 of Title 16 of the California Code of 12 Regulations before initiating emergency contraception drug therapy pursuant to this section. 13
- 14 (e) For each emergency contraception drug therapy initiated 15 pursuant to this section, the pharmacist shall provide the 16 recipient of the emergency contraception drugs with a standardized factsheet that includes, but is not limited to, the 17 indications for use of the drug, the appropriate method for using 18 the drug, the need for medical followup, and other appropriate 19 20 information. The board shall develop this form in consultation 21 with the State Department of Health Services, the American 22 College of Obstetricians and Gynecologists, the California 23 Pharmacists Association, and other health care organizations. The provisions of this section do not preclude the use of existing 24 25 publications developed by nationally recognized medical 26 organizations.
  - SEC. 10. Section 4112 of the Business and Professions Code is amended to read:
  - 4112. (a) Any pharmacy located outside this state that ships, mails, or delivers, in any manner, controlled substances, dangerous drugs, or dangerous devices into directly to patients in this state, or that performs prescription review, patient consultation, drug utilization review, medication therapy management, or other cognitive pharmacy services for patients in this state, shall be considered a nonresident pharmacy.
- (b) All nonresident pharmacies shall register with the board. 36 The board may register a nonresident pharmacy that is organized 37 38 as a limited liability company in the state in which it is licensed.
- (c) A nonresident pharmacy shall disclose to the board the 39 40 location, names, and titles of (1) its agent for service of process

—17— AB 2408

in this state, (2) all principal corporate officers, if any, and (3) all general partners, if any, and (4) all pharmacists who are dispensing controlled substances, dangerous drugs, or dangerous devices to residents of this state. A report containing this information shall be made on an annual basis and within 30 days after any change of office, corporate officer, or partner, or pharmacist.

- (d) All nonresident pharmacies shall comply with all lawful directions and requests for information from the regulatory or licensing agency of the state in which it is licensed as well as with all requests for information made by the board pursuant to this section. The nonresident pharmacy shall maintain, at all times, a valid unexpired license, permit, or registration to conduct the pharmacy in compliance with the laws of the state in which it is a resident. As a prerequisite to registering with the board, the nonresident pharmacy shall submit a copy of the most recent inspection report resulting from an inspection conducted by the regulatory or licensing agency of the state in which it is located.
- (e) All nonresident pharmacies shall maintain records of controlled substances, dangerous drugs, or dangerous devices dispensed to patients in this state so that the records are readily retrievable from the records of other drugs dispensed.
- (f) Any pharmacy subject to this section shall, during its regular hours of operation, but not less than six days per week, and for a minimum of 40 hours per week, provide a toll-free telephone service to facilitate communication between patients in this state and a pharmacist at the pharmacy who has access to the patient's records. This toll-free telephone number shall be disclosed on a label affixed to each container of drugs dispensed to patients in this state.
- (g) The board shall adopt regulations that apply the same requirements or standards for oral consultation to a nonresident pharmacy that operates pursuant to this section and ships, mails, or delivers any controlled substances, dangerous drugs, or dangerous devices to residents of this state, as are applied to an in-state pharmacy that operates pursuant to Section 4037 when the pharmacy ships, mails, or delivers any controlled substances, dangerous drugs, or dangerous devices to residents of this state. The board shall not adopt any regulations that require

AB 2408 — 18 —

1 face-to-face consultation for a prescription that is shipped, 2 mailed, or delivered to the patient. The regulations adopted 3 pursuant to this subdivision shall not result in any unnecessary 4 delay in patients receiving their medication.

- (h) The registration fee shall be the fee specified in subdivision (a) of Section 4400.
- (i) The registration requirements of this section shall apply only to a nonresident pharmacy that ships, mails, or delivers controlled substances, dangerous drugs, and dangerous devices into this state pursuant to a prescription.
- (j) Nothing in this section shall be construed to authorize the dispensing of contact lenses by nonresident pharmacists except as provided by Section 4124.
- SEC. 11. Section 4120 of the Business and Professions Code is amended to read:
- 4120. (a) A nonresident pharmacy shall not sell or distribute dangerous drugs or dangerous devices in this state through any person or media other than a wholesaler who has obtained a license pursuant to this chapter or through a selling or distribution outlet that is licensed as a wholesaler pursuant to this chapter without registering as a nonresident pharmacy.
- (b)—Applications for a nonresident pharmacy registration shall be made on a form furnished by the board. The board may require any information as the board deems reasonably necessary to carry out the purposes of this section.
- (b) Each application to conduct a nonresident pharmacy shall specify the type or types of pharmacy for which the application is submitted, pursuant to Section 4037. The applicant shall immediately notify the board of any requested addition, deletion, or other change in specified pharmacy type prior to licensure. After licensure, any change in specified pharmacy type shall be reported to the board, on a form to be furnished by the board, at least 30 calendar days prior to implementation or elimination of any activities permitted by the added, deleted, or changed type designation.
- 36 (c) The Legislature, by enacting this section, does not intend a 37 license issued to any nonresident pharmacy pursuant to this 38 section to change or affect the tax liability imposed by Chapter 3 39 (commencing with Section 23501) of Part 11 of Division 2 of the 40 Revenue and Taxation Code on any nonresident pharmacy.

—19 — AB 2408

(d) The Legislature, by enacting this section, does not intend a license issued to any nonresident pharmacy pursuant to this section to serve as any evidence that the nonresident pharmacy is doing business within this state.

- SEC. 12. Section 4201 of the Business and Professions Code is amended to read:
  - 4201. (a) Each application to conduct a pharmacy, wholesaler, or veterinary food-animal drug retailer, shall be made on a form furnished by the board, and shall state the name, address, usual occupation, and professional qualifications, if any, of the applicant. If the applicant is other than a natural person, the application shall state the information as to each person beneficially interested therein.
- (b) Each application to conduct a pharmacy shall specify the type or types of pharmacy for which the application is submitted, pursuant to Section 4037. The applicant shall immediately notify the board of any requested addition, deletion, or other change in specified pharmacy type prior to licensure. After licensure, any change in specified pharmacy type shall be reported to the board, on a form to be furnished by the board, at least 30 calendar days prior to implementation or elimination of any activities permitted by the added, deleted, or changed type designation.
- (c) As used in this section, and subject to subdivision (c), the term "person beneficially interested" means and includes:
- (1) If the applicant is a partnership or other unincorporated association, each partner or member.
- (2) If the applicant is a corporation, each of its officers, directors, and stockholders, provided that no natural person shall be deemed to be beneficially interested in a nonprofit corporation.
- (3) If the applicant is a limited liability company, each officer, manager, or member.
  - <del>(c)</del>

 (d) In any case where the applicant is a partnership or other unincorporated association, is a limited liability company, or is a corporation, and where the number of partners, members, or stockholders, as the case may be, exceeds five, the application shall so state, and shall further state the information required by subdivision (a) as to each of the five partners, members, or

stockholders who own the five largest interests in the applicant entity. Upon request by the executive officer, the applicant shall furnish the board with the information required by subdivision (a) as to partners, members, or stockholders not named in the application, or shall refer the board to an appropriate source of that information.

<del>(d)</del>

 (e) The application shall contain a statement to the effect that the applicant has not been convicted of a felony and has not violated any of the provisions of this chapter. If the applicant cannot make this statement, the application shall contain a statement of the violation, if any, or reasons which will prevent the applicant from being able to comply with the requirements with respect to the statement.

<del>(e)</del>

(f) Upon the approval of the application by the board and payment of the fee required by this chapter for each pharmacy, wholesaler, or veterinary food-animal drug retailer, the executive officer of the board shall issue a license to conduct a pharmacy, wholesaler, or veterinary food-animal drug retailer, if all of the provisions of this chapter have been complied with.

<del>(f)</del>

(g) Notwithstanding any other provision of law, the pharmacy license shall authorize the holder to conduct a pharmacy. The license shall be renewed annually and shall not be transferable.

<del>(2)</del>

(h) Notwithstanding any other provision of law, the wholesale license shall authorize the holder to wholesale dangerous drugs and dangerous devices. The license shall be renewed annually and shall not be transferable.

31 <del>(h</del>

(i) Notwithstanding any other provision of law, the veterinary food-animal drug retailer license shall authorize the holder thereof to conduct a veterinary food-animal drug retailer and to sell and dispense veterinary food-animal drugs as defined in Section 4042.

37 <del>(i)</del>

38 (j) For licenses referred to in subdivisions (f), (g), and (h), any change in the proposed beneficial ownership interest shall be

\_\_21\_\_ AB 2408

reported to the board within 30 days thereafter upon a form to be furnished by the board.

- (j) This section shall become operative on July 1, 2001.
- 4 SEC. 13. Section 4207 of the Business and Professions Code 5 is amended to read:
  - 4207. (a) Upon receipt of an application for a license and the applicable fee, the board shall make a thorough investigation to determine whether the applicant is qualified for the license being sought. The board shall also determine whether this article has been complied with, and shall investigate all matters directly related to the issuance of the license that may affect the public welfare.
  - (b) The board shall not investigate matters connected with the operation of a premises other than those matters solely related to the furnishing of dangerous drugs or dangerous devices, or to the performance or provision of prescription or drug order processing or review services or cognitive services, that might adversely affect the public welfare.
  - (c) The board shall deny an application for a license if the applicant does not qualify for the license being sought.
  - (d) Notwithstanding any other provision of law, the board may request any information it deems necessary to complete the application investigation required by this section, and a request for information that the board deems necessary in carrying out this section in any application or related form devised by the board shall not be required to be adopted by regulation pursuant to the Administrative Procedures Procedure Act (Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code).
  - SEC. 14. Section 4301 of the Business and Professions Code, as added by Section 44 of Chapter 857 of the Statutes of 2004, is amended to read:
- 4301. The board shall take action against any holder of a license who is guilty of unprofessional conduct or whose license has been procured by fraud or misrepresentation or issued by mistake. Unprofessional conduct shall include, but is not limited to, any of the following:
- 38 (a) Gross immorality.
- 39 (b) Incompetence.

(c) Gross negligence.

AB 2408 — 22 —

1 (d) The clearly excessive furnishing of controlled substances 2 in violation of subdivision (a) of Section 11153 of the Health and 3 Safety Code.

- (e) The clearly excessive furnishing of controlled substances in violation of subdivision (a) of Section 11153.5 of the Health and Safety Code. Factors to be considered in determining whether the furnishing of controlled substances is clearly excessive shall include, but not be limited to, the amount of controlled substances furnished, the previous ordering pattern of the customer (including size and frequency of orders), the type and size of the customer, and where and to whom the customer distributes its product.
- (f) The commission of any act involving moral turpitude, dishonesty, fraud, deceit, or corruption, whether the act is committed in the course of relations as a licensee or otherwise, and whether the act is a felony or misdemeanor or not.
- (g) Knowingly making or signing any certificate or other document that falsely represents the existence or nonexistence of a state of facts.
- (h) The administering to oneself, of any controlled substance, or the use of any dangerous drug or of alcoholic beverages to the extent or in a manner as to be dangerous or injurious to oneself, to a person holding a license under this chapter, or to any other person or to the public, or to the extent that the use impairs the ability of the person to conduct with safety to the public the practice authorized by the license.
- (i) Except as otherwise authorized by law, knowingly selling, furnishing, giving away, or administering or offering to sell, furnish, give away, or administer any controlled substance to an addict.
- 31 (j) The violation of any of the statutes of this state, *of any* 32 *other state*, or of the United States regulating controlled substances and dangerous drugs.
- 34 (k) The conviction of more than one misdemeanor or any 35 felony involving the use, consumption, or self-administration of 36 any dangerous drug or alcoholic beverage, or any combination of 37 those substances.
  - (1) The conviction of a crime substantially related to the qualifications, functions, and duties of a licensee under this chapter. The record of conviction of a violation of Chapter 13

-- 23 -- AB 2408

(commencing with Section 801) of Title 21 of the United States 2 Code regulating controlled substances or of a violation of the 3 statutes of this state regulating controlled substances or 4 dangerous drugs shall be conclusive evidence of unprofessional 5 conduct. In all other cases, the record of conviction shall be conclusive evidence only of the fact that the conviction occurred. 7 The board may inquire into the circumstances surrounding the 8 commission of the crime, in order to fix the degree of discipline 9 or, in the case of a conviction not involving controlled substances 10 or dangerous drugs, to determine if the conviction is of an 11 offense substantially related to the qualifications, functions, and 12 duties of a licensee under this chapter. A plea or verdict of guilty 13 or a conviction following a plea of nolo contendere is deemed to 14 be a conviction within the meaning of this provision. The board may take action when the time for appeal has elapsed, or the 15 16 judgment of conviction has been affirmed on appeal or when an 17 order granting probation is made suspending the imposition of sentence, irrespective of a subsequent order under Section 1203.4 18 19 of the Penal Code allowing the person to withdraw his or her plea 20 of guilty and to enter a plea of not guilty, or setting aside the 21 verdict of guilty, or dismissing the accusation, information, or 22 indictment.

(m) The cash compromise of a charge of violation of Chapter 13 (commencing with Section 801) of Title 21 of the United States Code regulating controlled substances or of Chapter 7 (commencing with Section 14000) of Part 3 of Division 9 of the Welfare and Institutions Code relating to the Medi-Cal program. The record of the compromise is conclusive evidence of unprofessional conduct.

23

24

25

26

2728

29

30

31

32

33

34

35

36

- (n) The revocation, suspension, or other discipline by another state of a license to practice pharmacy, operate a pharmacy, or do any other act for which a license is required by this chapter.
- (o) Violating or attempting to violate, directly or indirectly, or assisting in or abetting the violation of or conspiring to violate any provision or term of this chapter or of the applicable federal and state laws and regulations governing pharmacy, including regulations established by the board or by any other state or federal regulatory agency.
- 39 (p) Actions or conduct that would have warranted denial of a 40 license.

AB 2408 — 24 —

1

3

4

5

6

8

9

10

11

12 13

14

15

16 17

18 19

20

21

22

23

24

25

26

2728

30

31

32

33

34 35

36

37

38 39

(q) Engaging in any conduct that subverts or attempts to subvert an investigation of the board.

- (r) The selling, trading, transferring, or furnishing of drugs obtained pursuant to Section 256b of Title 42 of the United States Code to any person a licensee knows or reasonably should have known, not to be a patient of a covered entity, as defined in paragraph (4) of subsection (a) of Section 256b of Title 42 of the United States Code.
- (s) The clearly excessive furnishing of dangerous drugs by a wholesaler to a pharmacy that primarily or solely dispenses prescription drugs to patients of long-term care facilities. Factors to be considered in determining whether the furnishing of dangerous drugs is clearly excessive shall include, but not be limited to, the amount of dangerous drugs furnished to a pharmacy that primarily or solely dispenses prescription drugs to patients of long-term care facilities, the previous ordering pattern of the pharmacy, and the general patient population to whom the pharmacy distributes the dangerous drugs. That a wholesaler has established, and employs, a tracking system that complies with the requirements of subdivision (b) of Section 4164 shall be considered in determining whether there has been a violation of this subdivision. This provision shall not be interpreted to require a wholesaler to obtain personal medical information or be authorized to permit a wholesaler to have access to personal medical information except as otherwise authorized by Section 56 and following of the Civil Code.
  - (t) This section shall become operative on January 1, 2006. SEC. 15. Section 4303 of the Business and Professions Code

29 is repealed.

- 4303. (a) The board may deny, revoke, or suspend a nonresident pharmacy registration for failure to comply with any requirement of Section 4112, 4124, or 4340, for any significant or repeated failure to comply with Section 4074 or 4076, or for failure to comply with Section 11164 of the Health and Safety Code.
- (b) The board may deny, revoke, or suspend a nonresident pharmacy registration for conduct that causes serious bodily or serious psychological injury to a resident of this state if the board has referred the matter to the regulatory or licensing agency in the state in which the pharmacy is located and the regulatory or

\_\_ 25 \_\_ AB 2408

licensing agency fails to initiate an investigation within 45 days of the referral.

3 SEC. 16. Section 4303 is added to the Business and 4 Professions Code, to read:

- 4303. (a) The board may report any violation of the laws and regulations of this state, any other state, or of the United States, including, but not limited to, any violation of this chapter or of the regulations established by the board, to the appropriate regulatory or licensing agency of the state in which a nonresident pharmacy is a resident.
- (b) The board may deny, revoke, or suspend a nonresident pharmacy registration, issue a citation or letter of admonishment to a nonresident pharmacy, or take any other action against a nonresident pharmacy that the board may take against a resident pharmacy license, on any of the same grounds upon such action might be taken against a resident pharmacy.
- SEC. 17. Section 4306.5 of the Business and Professions Code is amended to read:
  - 4306.5. (a) Unprofessional conduct for a pharmacist may include acts any of the following:
  - (1) Acts or omissions that involve, in whole or in part, the inappropriate exercise of his or her education, training, or experience as a pharmacist, whether or not the act or omission arises in the course of the practice of pharmacy or the ownership, management, administration, or operation of a pharmacy or other entity licensed by the board.
- (2) Acts or omissions that involve, in whole or in part, the failure to exercise or implement his or her best professional judgment or corresponding responsibility with regard to the dispensing or furnishing of controlled substances, dangerous drugs, or dangerous devices or with regard to the provision of cognitive services.
- (3) Acts or omissions that involve, in whole or in part, the failure to consult appropriate patient, prescription, and other records pertaining to the performance of any pharmacy function.
- (b) For pharmacists who practice outside of a pharmacy premises, unprofessional conduct may include acts or omissions that involve, in whole or in part, the failure to fully maintain and retain appropriate patient-specific information pertaining to the performance of any pharmacy function.

SEC. 18. No reimbursement is required by this act pursuant to Section 6 of Article XIII B of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIII B of the California Constitution.

10 11 12

13

14

15

All matter omitted in this version of the bill appears in the bill as introduced in Assembly, February 23, 2006 (JR11)

O

# Bills of

Interest



# CALIFORNIA STATE BOARD OF PHARMACY BILL ANALYSIS

BILL NUMBER: AB 2583 VERSION: AMENDED MARCH 27, 2006

AUTHOR: NATION SPONSOR: AUTHOR

**RECOMMENDED POSITION:** 

SUBJECT: DISPENSING PRESCRIPTION DRUGS AND DEVICES: REFUSAL TO

DISPENSE

#### **Existing Law:**

1) States that no licentiate shall obstruct a patient in obtaining a prescription drug or device that has been legally prescribed or ordered for that patient. A violation of this section constitutes unprofessional conduct by the licentiate and shall subject the licentiate to disciplinary action by his or her licensing agency.

(B&P 733)

2) Requires a licentiate to dispense drugs and devices pursuant to a lawful order or prescription unless one of the following circumstances exists: 1) dispensing pursuant the prescription is contrary to law or the prescribed drug or device would cause a harmful drug interaction or would otherwise adversely affect the patient's medical condition; 2) the prescription drug or device is not in stock; or 3) the licentiate refuses on ethical, moral, or religious grounds to dispense a drug or device pursuant to an order or prescription, and the licentiate has previously notified his or her employer, in writing, of the drug or class of drugs to which he or she objects; and the employer can, provide a reasonable accommodation of the licentiate's objection by establishing protocols that ensure that the patient has timely access to the prescribed drug or device despite the licentiate's refusal to dispense the prescription or order. (B&P 733)

Requires every pharmacy to prominently a place conspicuous to and readable by prescription drug consumers a notice provided by the board concerning the availability of prescription price information, the possibility of generic drug product selection, and the type of services provided by pharmacies; alternatively, a written receipt that contains the required information on the notice may be provided to consumers to posting the notice in the pharmacy. (B&P 4122)

Specifies the wording of the Notice to Consumers that must be posted in accordance with B&P section 4122. (CCR 1707.2)

#### This Bill:

- 1) Requires the board create and provide to licentiates or licentiate's employers a sign informing patients of the following:
  - i. If a licentiate refuses to dispense a prescription drug or device based on ethical, moral, or religious grounds, the patient has a right to timely access to the prescribed drug or device.
  - ii. How a patient may file a complaint with the board, including contact information for the board. (B&P 733 Amended)

3) Requires the licentiate or licentiate's employer to place the sign in a location that is visible to patients and that is at or near the entrance of the business if a licentiate, pursuant to B&P 733, declines to dispense a prescription drug or device. (B&P 733 Amended)

#### Comment:

- 1) Author's Intent. The author's intent is to "ensure patients receive their prescription drugs in a timely manner, especially when a pharmacist chooses not to fill the prescription based on ethical, moral or religious reasons. A sign notifying a patient that a pharmacist will not dispense a drug or devise pursuant to a prescription will allow a patient to, among other options, choose a pharmacy that will fulfill the patient's needs. Waiting in line just to be rejected will only delay access to a prescribed drug or device."
- 2) Real Issue. The stated goal of SB 644 and AB 2583 has been to ensure that a patient has access to their prescribed medications while preserving a licentiate's has the right to refuse to fill a prescription based on ethical, moral or religious objections. While the goal of the measures has been broad based, almost all of the discussions on the bills have been exclusively on women's access to emergency contraception (EC). If access to EC is the true goal of the legislation, then AB 2583 and related discussions should focus on EC. Currently the board receives fewer than two complaints a year relating to EC access. Given that there are approximately 30,000-licensed pharmacists in the state the actions the bill proposes to fix the problem access to EC appear to be premature.
- **3)** Costs to the Board. The board estimates it would cost \$24,00 in fiscal year 2006-07 to comply with measure; annual cost thereafter would be approximately \$2,400 per fiscal year.

Fiscal Year 2006-07		
0.12 PY (AGPA) to create and gain approval for sign		
Initial Printing of 6,000 sign		\$12,000
Initial mailing cost (includes mailing tubes and postage \$2/sign)		\$12,000
	Total	\$24,000
Annual Cost beyond 2007		
Print and mail 600 sign to newly licensed pharmacies	Total	\$2,400

In cases where a pharmacy is newly licensed the board may include the sign in the same mailing tube as the Notice to Consumers required by B&P 4122; in this situation the cost would be considerably less and limited to the additional postage for additional weight of the sign in the mailing tube.

**4) Previous Legislation.** SB 644 (Chapter 417, Statutes of 2005) added B&P section 733 to the code to require a health care licentiate to dispense drugs and devices pursuant to a lawful prescription or order except in specified circumstances, including on ethical, moral, or religious grounds asserted by the licentiate. The board gained amendments to the measure that allows the board to cite and fine or issue letters of admonishment for violations of the measure's provisions.

#### 5) Support / Opposition.

Support: California National Organization for Women

Opposition: Capitol Resource Institute

California Society of Health-System Pharmacists

### 6) History.

Mar. 28	Re-referred to Com. on B. & P.
Mar. 27	From committee chair, with author's amendments: Amend, and re-refe
Mar. 20	Referred to Coms. on B. & P. and HEALTH
Feb. 27	Read first time.
Feb. 25	From printer. May be heard in committee March 27.
Feb. 27	Read first time.
Feb. 25	From printer. May be heard in committee March 27.
Feb 24	Introduced To print

#### AMENDED IN ASSEMBLY MARCH 27, 2006

CALIFORNIA LEGISLATURE—2005-06 REGULAR SESSION

#### ASSEMBLY BILL

No. 2583

#### **Introduced by Assembly Member Nation**

February 24, 2006

An act to amend Section 733 of the Business and Professions Code, relating to healing arts.

#### LEGISLATIVE COUNSEL'S DIGEST

AB 2583, as amended, Nation. Dispensing prescription drugs and devices: refusal to dispense.

Existing law prohibits a health care licentiate from obstructing a patient in obtaining a prescription drug or device, and requires the licentiate to dispense drugs and devices pursuant to a lawful prescription or order, except in specified circumstances, including on ethical, moral, or religious grounds asserted by the licentiate if certain requirements are met. Existing law authorizes the California State Board of Pharmacy to issue a citation for a violation of these provisions and authorizes its executive officer to issue a letter of admonishment for their violation.

This bill would require the board to create and provide a sign informing a patient of his or her right to timely access to a prescribed drug or device that a licentiate has refused to dispense based on ethical, moral, or religious grounds and informing a patient of how to file a complaint with the board. The bill would require licentiates authorized to make such a refusal, or their employers, to visibly place the sign at or near the entrance of the business.

Vote: majority. Appropriation: no. Fiscal committee: yes. State-mandated local program: no.

AB 2583 -2-

 The people of the State of California do enact as follows:

1 SECTION 1. Section 733 of the Business and Professions 2 Code is amended to read:

- 733. (a) No licentiate shall obstruct a patient in obtaining a prescription drug or device that has been legally prescribed or ordered for that patient. A violation of this section constitutes unprofessional conduct by the licentiate and shall subject the licentiate to disciplinary or administrative action by his or her licensing agency.
- (b) Notwithstanding any other provision of law, a licentiate shall dispense drugs and devices, as described in subdivision (a) of Section 4024, pursuant to a lawful order or prescription unless one of the following circumstances exists:
- (1) Based solely on the licentiate's professional training and judgment, dispensing pursuant to the order or the prescription is contrary to law, or the licentiate determines that the prescribed drug or device would cause a harmful drug interaction or would otherwise adversely affect the patient's medical condition.
- (2) The prescription drug or device is not in stock. If an order, other than an order described in Section 4019, or prescription cannot be dispensed because the drug or device is not in stock, the licentiate shall take one of the following actions:
- (A) Immediately notify the patient and arrange for the drug or device to be delivered to the site or directly to the patient in a timely manner.
- (B) Promptly transfer the prescription to another pharmacy known to stock the prescription drug or device that is near enough to the site from which the prescription or order is transferred, to ensure the patient has timely access to the drug or device.
- (C) Return the prescription to the patient and refer the patient. The licentiate shall make a reasonable effort to refer the patient to a pharmacy that stocks the prescription drug or device that is near enough to the referring site to ensure that the patient has timely access to the drug or device.
- 35 (3) The licentiate refuses on ethical, moral, or religious grounds to dispense a drug or device pursuant to an order or prescription.

-3- AB 2583

(A) A licentiate may decline to dispense a prescription drug or device on this basis only if the licentiate has previously notified his or her employer, in writing, of the drug or class of drugs to which he or she objects, and the licentiate's employer can, without creating undue hardship, provide a reasonable accommodation of the licentiate's objection. The licentiate's employer shall establish protocols that ensure that the patient has timely access to the prescribed drug or device despite the licentiate's refusal to dispense the prescription or order. For purposes of this section, "reasonable accommodation" and "undue hardship" shall have the same meaning as applied to those terms pursuant to subdivision (*l*) of Section 12940 of the Government Code.

- (B) The California State Board of Pharmacy shall create and provide to licentiates or licentiate's employers a sign informing patients—that, if of the following:
- (i) If a licentiate refuses to dispense a prescription drug or device based on ethical, moral, or religious grounds, the patient has a right to timely access to the prescribed drug or device. If
- (ii) How a patient may file a complaint with the board, including providing contact information for the board.
- (C) If a licentiate is authorized, pursuant to subparagraph (A), to decline to dispense a prescription drug or device, the licentiate or licentiate's employer shall place this sign the sign described in subparagraph (B) in a location that is visible to patients and that is at or near the entrance of the business.
- (c) For the purposes of this section, "prescription drug or device" has the same meaning as the definition in Section 4022.
- (d) The provisions of this section shall apply to the drug therapy described in paragraph (8) of subdivision (a) of Section 4052.
- 32 (e) This section imposes no duty on a licentiate to dispense a 33 drug or device pursuant to a prescription or order without 34 payment for the drug or device, including payment directly by 35 the patient or through a third party payer accepted by the 36 licentiate or payment of any required copayment by the patient.



## CALIFORNIA STATE BOARD OF PHARMACY BILL ANALYSIS

BILL NUMBER: AB 2743

**VERSION: INTRODUCED** 

**AUTHOR: MATTHEWS** 

SPONSOR: CA. RETAILERS ASSOCIATION (CRA)

**RECOMMENDED POSITION:** 

SUBJECT: PHARMACISTS: ANCILLARY PERSONNEL

#### **Existing Law:**

1) Limits the number of intern pharmacists a pharmacist can supervise at any one time to no more than two. (B&P 4114)

- 2) Limits the number of pharmacy technicians a pharmacy with only one pharmacist can have to no more than one. (B&P 4115)
- 3) Caps the ratio of pharmacists to pharmacy technicians for pharmacies with more than one pharmacist to no more than 2:1, after the first pharmacist (when a 1:1 ratio is required).

  (B&P 4115)
- 4) Limits the number of pharmacy technician trainees a pharmacist may supervise at any time to one. (B&P 4115)
- 5) Permits a pharmacist to determine the number of non-licensed personnel he or she may supervise that perform the duties of typing a prescription label or otherwise enter prescription information into a computer record system. (CCR 1793.3)

#### This Bill:

- 1) Limits number of ancillary personnel a pharmacy may have to no more than eight per pharmacist. (B&P 4115.3 Added)
- 2) Permits each pharmacist to have discretion as to how many ancillary personnel, within this limit, he or she supervises, subject to the limits set forth in B&P sections 4114, 4115, and 4115.5. (B&P 4115.3 Added)
- 2) Defines "ancillary personnel" to include pharmacy technicians, pharmacy technician trainees, interns, clerks, and typists.

  (B&P 4115.3 Added)

#### Comment:

1) Author's Intent. The author and sponsor's intent is to increase the pharmacy technician to pharmacist ratio allowed in a pharmacy. (The current ratio is 2:1 when there are two or more pharmacists in a pharmacy.) The sponsor hopes to achieve the increase by limiting the number of ancillary personnel allowed in a pharmacy. The sponsor is currently working with those that

may oppose the bill. If the sponsor is successful in eliminating opposition to the bill the bill will likely be amended to reflect a new pharmacy technician to pharmacist ratio and ancillary personnel to pharmacist ratio.

- **2) Board History on Issue.** The board reviewed the issue of staffing ratios in the November 2001, *Pharmacy Manpower Task Force Report* and subsequently set the staffing ratio for community pharmacies at 4:1; that is one pharmacist may supervise up to two interns, one technician, and one technician in training. Subsequent legislation authorized a second and additional pharmacist to supervise two technicians (a ration of 5:1). The board removed a regulation on the limit on the number of clerk typist that a pharmacist may supervise.
- 3) Other States Pharmacy Technicians to Pharmacist Ratios. The staffing ratio of pharmacy technicians to pharmacist varies from state to state; seven states have a ratio of 4:1, three states have a ratio of 3:1, and fifteen states have a ratio similar to California's of 2:1.
- **4) Suggested Amendment.** As currently drafted AB 2743 would restore the "clerk typist" ratio of staff a pharmacist may supervise. If the measure moves forward a definition of "clerk typist" should be amended into the bill.

#### 5) History.

2006

Mar. 20 Referred to Com. on B. & P.

Feb. 25 From printer. May be heard in committee March 27.

Feb. 24 Introduced. To print.

#### **Introduced by Assembly Member Matthews**

February 24, 2006

An act to add Section 4115.3 to the Business and Professions Code, relating to healing arts.

#### LEGISLATIVE COUNSEL'S DIGEST

AB 2743, as introduced, Matthews. Pharmacists: ancillary personnel.

Existing law, the Pharmacy Law, the violation of which is a crime, provides for the licensing and regulation of the practice of pharmacy by the California State Board of Pharmacy. Existing law provides that a pharmacy with only one pharmacist shall have no more than one pharmacy technician performing specified tasks, and makes other provisions for the supervision of intern pharmacists, pharmacy technicians, and pharmacy technician trainees by a pharmacist.

This bill would prohibit a pharmacy from employing more than 8 ancillary personnel, as defined, per pharmacist. The bill would give a pharmacist discretion as to how many personnel he or she supervises, subject to the limits of existing law. Because this bill would create a new prohibition under the Pharmacy Law, the violation of which would be a crime, it would impose a state-mandated local program.

The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.

This bill would provide that no reimbursement is required by this act for a specified reason.

AB 2743 — 2 —

Vote: majority. Appropriation: no. Fiscal committee: yes. State-mandated local program: yes.

The people of the State of California do enact as follows:

- 1 SECTION 1. Section 4115.3 is added to the Business and 2 Professions Code, to read:
- 4115.3. (a) A pharmacy shall have no more than eight ancillary personnel per pharmacist. Each pharmacist shall have individual discretion as to how many ancillary personnel, within this limit, he or she supervises, subject to the limits set forth in
  - Sections 4114, 4115, and 4115.5.
- 8 (b) For purposes of this section, "ancillary personnel" includes 9 pharmacy technicians, pharmacy technician trainees, interns, 10 clerks, and typists.
- SEC. 2. No reimbursement is required by this act pursuant to Section 6 of Article XIII B of the California Constitution because
- 13 the only costs that may be incurred by a local agency or school
- 14 district will be incurred because this act creates a new crime or
- 15 infraction, eliminates a crime or infraction, or changes the
- 16 penalty for a crime or infraction, within the meaning of Section
- 17 17556 of the Government Code, or changes the definition of a
- 18 crime within the meaning of Section 6 of Article XIII B of the
- 19 California Constitution.



### CALIFORNIA STATE BOARD OF PHARMACY BILL ANALYSIS

BILL NUMBER: AB 2986 VERSION: AMENDED APRIL 5, 2006

AUTHOR: MULLIN SPONSOR: DEPARTMENT OF JUSTICE

**RECOMMENDED POSITION:** 

SUBJECT: CONTROLLED SUBSTANCES: PRESCRIPTION REQUIREMENTS

#### **Existing Law:**

1) Describes the required security features of controlled substances prescription forms.

(H&S 11162.1)

- 2) Describes the required information that must be on a controlled substances prescription form for a person to fill, compound, or dispense a prescription for a controlled substance.

  (H&S 11164)
- 3) Authorizes a prescriber or any agent of the prescriber on behalf of the prescriber to orally or electronically transmit a prescription for a controlled substance classified in Schedule III, IV.

  (H&S 11164)
- 4) Requires DOJ to maintain the Controlled Substance Utilization Review and Evaluation System (CURES) for monitoring the prescribing and dispensing of Schedule II and III controlled substances by all practitioners authorized to prescribe or dispense these controlled substances.

  (H&S 11165)
- 5 Requires pharmacies to report the following information to DOJ for Schedule II and III controlled substances: full name, address, gender, and date of birth of the patient; the prescriber's category of licensure and license number; federal controlled substance registration number; and the state medical license number of any prescriber using the federal controlled substance registration number of a government-exempt facility; pharmacy prescription number, license number, and federal controlled substance registration number; the NDC (National Drug Code) number of the controlled substance dispensed; the quantity of the controlled substance dispensed; the diagnosis code; date of the prescription and date of the dispensing the prescription. (H&S 11165)
- 6) Permits a licensed health care practitioner eligible to prescribe Schedule II or III controlled substances or a pharmacist to make a written request for, and the DOJ to release to that practitioner or pharmacist, the history of controlled substances dispensed to an individual under his or her care based on data contained in CURES. (H&S 11165.1)
- 7) Requires every practitioner, other than a pharmacist, who prescribes or administers a controlled substance classified in Schedule II to make a record that, as to the transaction, shows all of the information in H&S 11165. (H&S 11190)

#### This Bill:

- 1) Requires secure tamper-resistant prescription forms to include the following preprinted information on the forms in addition to what is currently required:
  - The name, address, and telephone number of the ultimate user or research subject, or the contact information as determined by the Secretary of the United States Department of Health and Human Services.
  - Check boxes so that the prescriber must indicate the number of refills and whether the prescription is a first-time request.
  - The date of origin of the prescription.

(H&S 11162.1 Amended)

- 2) Requires information listed in H&S 11162.1 to be on the security prescription form for a person to fill, compound, or dispense a prescription for a controlled substance. (H&S 11164 Amended)
- 3) Requires a dispensing pharmacy to provide DOJ the following information, in addition to what is currently required, for each Schedule II, III, or IV prescription it dispenses:
  - The name, address, and telephone number of the ultimate user or research subject, or the contact information as determined by the Secretary of the United States Department of Health and Human Services.
  - Check boxes so that the prescriber may indicate the number of refills and whether the prescription is a first time request.
  - The date of origin of the prescription.

(H&S 11165 Amended)

- 4) Requires the CURES program to monitor and report the prescribing and dispensing of Schedule II, III, IV controlled substances by all practitioners authorized to prescribe or dispense these controlled substances. (H&S 11165 and 11165.1 Amended)
- 5) Requires every practitioner, other than a pharmacist, who prescribes or administers a controlled substance classified as Schedule II to make a record that, as to the transaction, shows all of the information in H&S 11165. (H&S 11190 Amended)
- 6) Changes the controlled substances reporting requirement to DOJ from monthly to weekly.

  (H&S 11190 Amended)

#### Comment:

- 1) Author's Intent. The bill is sponsored the DOJ. The author's intent is to align California's Prescription Monitoring Program (PMP) with the federal National All Schedules Prescription Electronic Reporting Act of 2005 (NASPER Act). This proposal will ensure state compliance with new federal mandates.
- **2) NASPER Act and CURES.** The NASPER Act was signed into law by President Bush on August 11, 2005. The Act requires all states to establish a PMP or enhance their current state PMP.

The NASPER Act imposes several mandates not previously required by DOJ's Controlled Substances Utilization Review and Evaluation System (CURES) program. These mandates include:

- Capturing Schedule IV controlled substances data.
- Requiring dispensers to report to states within one week of each dispensing of a controlled substance

- Requiring specific data, such as patient telephone number, number of refills, and whether the prescription is for a refill or a first-time prescription.
- Requiring secure prescription forms include a refill notation; under current law this notation is optional at the prescriber's request.
- Requiring dispensers to report information in an electronic format specified by the U.S. Secretary of Health and Human Services, with an exception that the state may waive the required format with respect to individual dispensers.
- 3) Concerns with the Measure. The board reviewed AB 2986 as a legislative proposal at the board's meeting in February 2006. At that meeting discussion among board members and staff yielded two main concerns with the proposal as now contained in AB 2986, they are:
  - 1. What happens if a patient cannot provide a telephone number or an address? (Can a pharmacist add this information?)
  - 2. "Date of issue" versus "date of origin."

Not discussed at the meeting, but may be raised as a related issue is, is there a necessity to continue to use specialized prescription forms for controlled substances? This issue is raised in SB 1366, a related bill, that would amend overlapping sections of law delete the requirement that prescriptions for controlled substances be written on security printer prescription forms.

- **4)** Related Legislation. SB 1366 (Aanestad) would eliminate the required use of specialized prescription forms by physicians and surgeons when issuing prescriptions for controlled substances. SB 1366 is set to be heard in the Senate Public Safety Committee on April 24, 2006.
- **5) Previous Legislation.** SB 734 (Chapter 487, Statues of 2005), sponsored the DOJ, provided clean-up changes to facilitate the effective operation of the CURES, the prescribing and dispensing of controlled substances, and the program duties of the Bureau of Narcotics Enforcement. Among other provisions the measure transferred the approval of security printers from the board to the DOJ. The board sought a technical amendment to cap board spending for CURES to the amount of money appropriated by the state budget.

SB 151 (Statutes of 2003, Chapter 406) implementing the "Pain Treatment and Diversion Act of 2003, "the Controlled Substances Utilization Review and Evaluation System (CURES) became permanent.

AB 2018 (Chapter 1092, Statutes of 2002) provided changes to the triplicate pad and established a process for correction of prescription errors.

AB 2693 (Chapter 789, Statutes of 1998) exempted Schedule II controlled substances for patients with terminal illnesses from triplicate prescription form requirements.

AB 3042 (Chapter 738, Statutes of 1996) created the CURES program on a pilot basis.

#### 6) Support / Opposition.

Support: California Narcotic Officers' Association

Opposition: None on file at this time.

#### 7) History.

2006

Feb. 27 Read first time.

Feb. 25 From printer. May be heard in committee March 27.

Feb. 24 Introduced. To print.

#### AMENDED IN ASSEMBLY APRIL 5, 2006

CALIFORNIA LEGISLATURE—2005-06 REGULAR SESSION

#### ASSEMBLY BILL

No. 2986

#### **Introduced by Assembly Member Mullin**

February 24, 2006

An act to amend Sections 11162.1, 11164, 11165, 11165.1, and 11190 of the Health and Safety Code, relating to controlled substances.

#### LEGISLATIVE COUNSEL'S DIGEST

AB 2986, as amended, Mullin. Controlled substances: prescription requirements.

(1) Existing law provides that no person shall prescribe a controlled substance, nor shall any person fill, compound, or dispense such a prescription unless the prescription complies with specified requirements; the prescription must be printed with specified features and must set forth specified information. Unless otherwise specified, a violation of any of these provisions is a misdemeanor, punishable as specified.

This bill would require the prescription forms to also include the name, address, and telephone number of the ultimate user or research subject, or the contact information as determined by the U.S. Secretary of Health and Human Services; check boxes so that the prescriber may indicate that a prescription is a first-time request or that a specified the number of refills of the prescription have been ordered since the first prescription; and the date of origin of the prescription and whether the prescription is a first-time request or a refill.

AB 2986 — 2 —

(2) Existing law provides for the electronic monitoring and reporting of the prescribing and dispensing of Schedule II and Schedule III controlled substances pursuant to the Controlled Substance Utilization Review and Evaluation System (CURES) program.

This bill would provide that the CURES program shall also monitor and report on the prescribing and dispensing of Schedule IV controlled substances.

(3) Existing law provides that every practitioner, other than a pharmacist, who prescribes or administers a Schedule II controlled substance shall make a record of the transaction and shall provide the Department of Justice with information relating to the transaction on a monthly basis, as specified.

This bill would instead require the information to be provided to the Department of Justice on a weekly basis.

(4) The bill would make conforming changes to related provisions. By revising existing crimes, this bill would impose a state-mandated local program.

The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.

This bill would provide that no reimbursement is required by this act for a specified reason.

Vote: majority. Appropriation: no. Fiscal committee: yes. State-mandated local program: yes.

The people of the State of California do enact as follows:

- SECTION 1. Section 11162.1 of the Health and Safety Code is amended to read:
- 3 11162.1. (a) The prescription forms for controlled substances 4 shall be printed with the following features:
- 5 (1) A latent, repetitive "void" pattern shall be printed across 6 the entire front of the prescription blank; if a prescription is 7 scanned or photocopied, the word "void" shall appear in a pattern 8 across the entire front of the prescription.
- 9 (2) A watermark shall be printed on the backside of the 10 prescription blank; the watermark shall consist of the words 11 "California Security Prescription."

-3- AB 2986

- 1 (3) A chemical void protection that prevents alteration by 2 chemical washing.
  - (4) A feature printed in thermo-chromic ink.
- 4 (5) An area of opaque writing so that the writing disappears if the prescription is lightened.
- 6 (6) A description of the security features included on each prescription form.
- 8 (7) (A) Six quantity check off boxes shall be printed on the 9 form and the following quantities shall appear:
- 10 1-24

3

- 11 25-49
- 12 50-74
- 13 75-100

19

20 21

22 23

24

2526

27

28 29

30 31

32

- 14 101-150
- 15 151 and over.
- 16 (B) In conjunction with the quantity boxes, a space shall be 17 provided to designate the units referenced in the quantity boxes 18 when the drug is not in tablet or capsule form.
  - (8) Prescription blanks shall contain a statement printed on the bottom of the prescription blank that the "Prescription is void if the number of drugs prescribed is not noted."
  - (9) The preprinted name, category of licensure, license number, federal controlled substance registration number of the prescribing practitioner.
  - (10) The telephone number of the ultimate user or research subject, or the contact information as determined by the Secretary of the United States Department of Health and Human Services
  - (11) Check boxes shall be printed on the form so that the prescriber may indicate that a prescription is a first-time request or that a specified number of refills of the prescription have been ordered since the first prescription. prescriber may indicate the number of refills ordered and whether the prescription is a first-time request or a refill.
- 35 (12) The date of origin of the prescription.
- 36 (13) A check box indicating the prescriber's order not to 37 substitute.
- 38 (14) An identifying number assigned to the approved security printer by the Department of Justice.

AB 2986 —4—

1 (15) (A) A check box by the name of each prescriber when a 2 prescription form lists multiple prescribers.

- (B) Each prescriber who signs the prescription form shall identify himself or herself as the prescriber by checking the box by their name.
- (b) Each batch of controlled substance prescription forms shall have the lot number printed on the form and each form within that batch shall be numbered sequentially beginning with the numeral one.
- (c) (1) A prescriber designated by a licensed health care facility, a clinic specified in Section 1200, or a clinic specified in subdivision (a) of Section 1206 that has 25 or more physicians or surgeons may order controlled substance prescription forms for use by prescribers when treating patients in that facility without the information required in paragraph (9) of subdivision (a) or paragraph (3) of this subdivision.
- (2) Forms ordered pursuant to this subdivision shall have the name, category of licensure, license number, and federal controlled substance registration number of the designated prescriber and the name, address, category of licensure, and license number of the licensed health care facility the clinic specified in Section 1200, or the clinic specified in subdivision (a) of Section 1206 that has 25 or more physicians or surgeons preprinted on the form.
- (3) Forms ordered pursuant to this section shall not be valid prescriptions without the name, category of licensure, license number, and federal controlled substance registration number of the prescriber on the form.
- (4) (A) Except as provided in subparagraph (B), the designated prescriber shall maintain a record of the prescribers to whom the controlled substance prescription forms are issued, that shall include the name, category of licensure, license number, federal controlled substance registration number, and the quantity of controlled substance prescription forms issued to each prescriber and be maintained in the health facility for three years.
- (B) Forms ordered pursuant to this subdivision that are printed by a computerized prescription generation system shall not be subject to the requirements set forth in subparagraph (A) or paragraph (7) of subdivision (a). Forms printed pursuant to this subdivision that are printed by a computerized prescription

-5- AB 2986

generation system may contain the prescriber's name, category of professional licensure, license number, federal controlled substance registration number, and the date of the prescription.

(d) This section shall become operative on July 1, 2004.

- SEC. 2. Section 11164 of the Health and Safety Code is amended to read:
- 11164. Except as provided in Section 11167, no person shall prescribe a controlled substance, nor shall any person fill, compound, or dispense a prescription for a controlled substance, unless it complies with the requirements of this section.
- (a) Each prescription for a controlled substance classified in Schedule II, III, IV, or V, except as authorized by subdivision (b), shall be made on a controlled substance prescription form as specified in Section 11162.1 and shall meet the following requirements:
- (1) The prescription shall be signed and dated by the prescriber in ink and shall contain the prescriber's address and telephone number; the *name*, *address*, *and* telephone number of the ultimate user or research subject, or contact information as determined by the Secretary of the United States Department of Health and Human Services; refill information, such as the number of refills ordered and whether the prescription is a first-time request or a refill; the date of origin of the prescription; and the name, quantity, strength, and directions for use of the controlled substance prescribed.
- (2) The prescription shall also contain the address of the person for whom the controlled substance is prescribed. If the prescriber does not specify this address on the prescription, the pharmacist filling the prescription or an employee acting under the direction of the pharmacist shall write or type the address on the prescription or maintain this information in a readily retrievable form in the pharmacy.
- (b) (1) Notwithstanding paragraph (1) of subdivision (a) of Section 11162.1, any controlled substance classified in Schedule III, IV, or V may be dispensed upon an oral or electronically transmitted prescription, which shall be produced in hard copy form and signed and dated by the pharmacist filling the prescription or by any other person expressly authorized by provisions of the Business and Professions Code. Any person who transmits, maintains, or receives any electronically

AB 2986 — 6 —

1

3

9

10

11

12

13

14 15

16

17

18

19

20

21 22

23

24

25

transmitted prescription shall ensure the security, integrity, authority, and confidentiality of the prescription.

- (2) The date of issue of the prescription and all the information required for a written prescription by subdivision (a) shall be included in the written record of the prescription; the pharmacist need not include the address, telephone number, license classification, or federal registry number of the prescriber or the address of the patient on the hard copy, if that information is readily retrievable in the pharmacy.
- (3) Pursuant to an authorization of the prescriber, any agent of the prescriber on behalf of the prescriber may orally or electronically transmit a prescription for a controlled substance classified in Schedule III, IV, or V, if in these cases the written record of the prescription required by this subdivision specifies the name of the agent of the prescriber transmitting the prescription.
- (c) The use of commonly used abbreviations shall not invalidate an otherwise valid prescription.
- (d) Notwithstanding any provision of subdivisions (a) and (b), prescriptions for a controlled substance classified in Schedule V may be for more than one person in the same family with the same medical need.
- (e) This section shall become operative on January 1, 2005. SEC. 3. Section 11165 of the Health and Safety Code is amended to read:
- 26 (a) To assist law enforcement and regulatory 11165. 27 agencies in their efforts to control the diversion and resultant 28 abuse of Schedule II, Schedule III, and Schedule IV controlled 29 substances, and for statistical analysis, education, and research, 30 the Department of Justice shall, contingent upon the availability 31 of adequate funds from the Contingent Fund of the Medical 32 Board of California, the Pharmacy Board Contingent Fund, the 33 State Dentistry Fund, the Board of Registered Nursing Fund, and 34 the Osteopathic Medical Board of California Contingent Fund, maintain the Controlled Substance Utilization Review and 35 Evaluation System (CURES) for the electronic monitoring of the 36 37 prescribing and dispensing of Schedule II, Schedule III, and 38 Schedule IV controlled substances by all practitioners authorized 39 to prescribe or dispense these controlled substances.

-7- AB 2986

(b) The reporting of Schedule III and Schedule IV controlled substance prescriptions to CURES shall be contingent upon the availability of adequate funds from the Department of Justice. The Department of Justice may seek and use grant funds to pay the costs incurred from the reporting of controlled substance prescriptions to CURES. Funds shall not be appropriated from the Contingent Fund of the Medical Board of California, the Pharmacy Board Contingent Fund, the State Dentistry Fund, the Board of Registered Nursing Fund, the Naturopathic Doctor's Fund, or the Osteopathic Medical Board of California Contingent Fund to pay the costs of reporting Schedule III and Schedule IV controlled substance prescriptions to CURES. 

- (c) CURES shall operate under existing provisions of law to safeguard the privacy and confidentiality of patients. Data obtained from CURES shall only be provided to appropriate state, local, and federal persons or public agencies for disciplinary, civil, or criminal purposes and to other agencies or entities, as determined by the Department of Justice, for the purpose of educating practitioners and others in lieu of disciplinary, civil, or criminal actions. Data may be provided to public or private entities, as approved by the Department of Justice, for educational, peer review, statistical, or research purposes, provided that patient information, including any information that may identify the patient, is not compromised. Further, data disclosed to any individual or agency as described in this subdivision shall not be disclosed, sold, or transferred to any third party.
- (d) For each prescription for a Schedule II, Schedule III, or Schedule IV controlled substance, the dispensing pharmacy shall provide the following information to the Department of Justice in a frequency and format specified by the Department of Justice:
- (1) Full name, address, *and the* telephone number of the ultimate user or research subject, or contact information as determined by the Secretary of the United States Department of Health and Human Services, *and the* gender, and date of birth of the patient.
- 37 (2) The prescriber's category of licensure and license number; 38 federal controlled substance registration number; and the state 39 medical license number of any prescriber using the federal

AB 2986 — 8 —

1 controlled substance registration number of a 2 government-exempt facility.

- 3 (3) Pharmacy prescription number, license number, and 4 federal controlled substance registration number.
- 5 (4) NDC (National Drug Code) number of the controlled substance dispensed.
  - (5) Quantity of the controlled substance dispensed.
  - (6) ICD-9 (diagnosis code), if available.
- 9 (7) Number of refills ordered.

7

8

12

13 14

15

16

17

18 19

20

21

22

23

24

25

- 10 (8) Whether the drug was dispensed as a refill—or of a prescription or as a first-time request.
  - (9) Date of origin of the prescription.
  - (10) Date of dispensing of the prescription.
  - (e) This section shall become operative on January 1, 2005.
  - SEC. 4. Section 11165.1 of the Health and Safety Code is amended to read:
  - 11165.1. (a) (1) A licensed health care practitioner eligible to prescribe Schedule II, Schedule III, or Schedule IV controlled substances or a pharmacist may make a written request for, and the Department of Justice may release to that practitioner or pharmacist, the history of controlled substances dispensed to an individual under his or her care based on data contained in CURES.
  - (2) Any request for, or release of, a controlled substance history pursuant to this section shall be made in accordance with guidelines developed by the Department of Justice.
- (b) In order to prevent the inappropriate, improper, or illegal use of Schedule II, Schedule III, or Schedule IV controlled substances, the Department of Justice may initiate the referral of the history of controlled substances dispensed to an individual based on data contained in CURES to licensed health care practitioners, pharmacists, or both, providing care or services to the individual.
- 34 (c) The history of controlled substances dispensed to an 35 individual based on data contained in CURES that is received by 36 a practitioner or pharmacist from the Department of Justice 37 pursuant to this section shall be considered medical information 38 subject to the provisions of the Confidentiality of Medical 39 Information Act contained in Part 2.6 (commencing with Section 40 56) of Division 1 of the Civil Code.

-9- AB 2986

- 1 SEC. 5. Section 11190 of the Health and Safety Code is 2 amended to read:
- 11190. (a) Every practitioner, other than a pharmacist, who prescribes or administers a controlled substance classified in Schedule II shall make a record that, as to the transaction, shows all of the following:
  - (1) The name and address of the patient.
  - (2) The date.

7

8

9

10

14 15

16 17

18 19

20 21

22

23

24

26

27

28 29

30

32

35

- (3) The character, including the name and strength, and quantity of controlled substances involved.
- 11 (b) The prescriber's record shall show the pathology and 12 purpose for which the controlled substance was administered or 13 prescribed.
  - (c) (1) For each prescription for a Schedule III or Schedule III controlled substance that is dispensed by a prescriber pursuant to Section 4170 of the Business and Professions Code, the prescriber shall record and maintain the following information:
  - (A) Full name, address, *and the* telephone number of the ultimate user or research subject, or contact information as determined by the Secretary of the United States Department of Health and Human Services, *and the* gender, and date of birth of the patient.
  - (B) The prescriber's category of licensure and license number; federal controlled substance registration number; and the state medical license number of any prescriber using the federal controlled substance registration number of a government-exempt facility.
  - (C) NDC (National Drug Code) number of the controlled substance dispensed.
    - (D) Quantity of the controlled substance dispensed.
- 31 (E) ICD-9 (diagnosis code), if available.
  - (F) Number of refills ordered.
- 33 (G) Whether the drug was dispensed as a refill of a prescription or as a first-time request.
  - (H) Date of origin of the prescription.
- 36 (2) Each prescriber that dispenses controlled substances shall 37 provide the Department of Justice the information required by 38 this subdivision on a weekly basis in a format set by the 39 Department of Justice pursuant to regulation.
  - (d) This section shall become operative on January 1, 2005.

**— 10 —** 

#### **AB 2986**

- SEC. 6. No reimbursement is required by this act pursuant to Section 6 of Article XIII B of the California Constitution because
- 3 the only costs that may be incurred by a local agency or school
- 4 district will be incurred because this act creates a new crime or
- 5 infraction, eliminates a crime or infraction, or changes the
- 6 penalty for a crime or infraction, within the meaning of Section
- 7 17556 of the Government Code, or changes the definition of a
- 8 crime within the meaning of Section 6 of Article XIII B of the
- 9 California Constitution.



### CALIFORNIA STATE BOARD OF PHARMACY BILL ANALYSIS

**BILL NUMBER: SB 1366** 

**VERSION: AMENDED APRIL 4, 2006** 

AUTHOR: AANESTAD

SPONSOR: CALIFORNIA MEDICAL ASSOCIATION

**RECOMMENDED POSITION:** 

SUBJECT: CONTROLLED SUBSTANCES: SPECIALIZED PRESCRIPTION PADS

#### **Existing Law:**

1) Requires physicians and surgeons to obtain and use forms for controlled substances from printers that have been approved by the Department of Justice when prescribing controlled substances.

(H&S 11161.5)

2) Specifies the preprinted requirements for controlled substances forms.

(H&S 11162.1)

3) Specifies the type of information that is required to be filled in on a prescription for schedule II-V drugs. (H&S 11162.1)

#### This Bill:

- 1) Eliminates the required use of specialized secure prescription pads for prescribing all scheduled drugs. As such, requirements to license security printers are also repealed.

  (H&S 11161, 11161.7, 11162.6, 11167 Amended, 11161.5, 11162.1 Repealed)
- 2) Retains the requirements that prescriptions for Schedule II-V drugs contain specified information, such as the prescription shall be signed and dated by the prescriber, in ink and shall contain the prescriber's address and telephone number; the name of the person for whom the controlled substance is prescribed; and the name, quantity, strength, and directions for use of the controlled substance prescribed.

  (H&S 11164 Amended)
- 3) Repeals the terminally ill or H&S 11159.2 exemption prescriptions. Repeals the requirement that a prescription for a Schedule II controlled substance for use by a patient who has a terminal illness shall meet specified requirements. (H&S 11159.2 Repealed)
- 4) Eliminates the requirement that the board must notify security printers when a prescriber's authority to prescribe controlled substances is restricted by law enforcement or licensing board.

  (H&S 11161.7 Amended)

#### Comment:

1) Author's Intent. The author's intent is to eliminate special prescription forms for prescribing controlled substance drugs, because in part, there is no evidence available to show that the use of specialized pads has reduced the level of illegal use or dissemination of controlled drugs. The author believes the pubic is better served by tracking controlled substances through the

Controlled Substance Utilization Review and Evaluation System (CURES) electronic surveillance system.

2) Brief History of Controlled Substance Forms and Tracking in CA. In 1939, California became the first state to instituted the use of specialized triplicate prescription forms to stem the abuse of selected dangerous drugs. Over the years the types of prescribed drugs requiring a triplicate form was expanded to include Schedule II-V drugs. In 2004, SB 151 eliminated the requirement for the use of triplicate forms and replaced it with a requirement to use new security printer forms issued by licensed printers.

In 1996, CURES was created to electronically monitor the prescribing, dispensing, and use of schedule II drugs. While this program initiated as a pilot program it has since become a permanent program and been expanded to track schedule II and III drugs.

In 2006, California has the distinction of being one of three states that still requires the use of specialized prescription forms for prescribing schedule drugs (see attached chart). Most other states have moved away from the specialized forms and rely on CURES, like monitoring programs to identify the misuse and abuse of scheduled drugs.

3) Related Legislation. AB 2986 (Mullin) Controlled substances, prescription requirements, sponsored by the Department of Justice, would require security prescription forms to also include the telephone number of the ultimate user or research subject, or the contact information as determined by the U.S. Secretary of Health and Human Services; check boxes so that the prescriber may indicate that a prescription is a first-time request or that a specified number of refills of the prescription have been ordered since the first prescription; and the date of origin of the prescription.

#### 4) Previous Legislation.

SB 734 (Chapter 487, Statutes of 2005) made clean-up changes to facilitate the effective operation of the CURES, the prescribing and dispensing of controlled substances, and the program duties of the Bureau of Narcotics Enforcement. Among other provisions it transfered the approval of security printers from the board to the Department of Justice.

SB 151 (Chapter 406, Statutes of 2003) implementing the "Pain Treatment and Diversion Act of 2003," the Controlled Substances Utilization Review and Evaluation System (CURES) became permanent.

AB 2018 (Chapter 1092, Statutes of 2002) provided changes to the triplicate pad and established a process for correction of prescription errors.

AB 2693 (Chapter 789, Statutes of 1998) exempted Schedule II controlled substances for patients with terminal illnesses from triplicate prescription form requirements.

AB 3042 (Chapter 738, Statutes of 1996) created the CURES program on a pilot basis.

#### 5) History.

2006	
Apr. 6	Set for hearing April 25.
Apr. 5	Re-referred to Com. on PUB. S.
Apr. 4	From committee with author's amendments. Read second time. Amended. Re-
	referred to committee.
Mar. 2	To Com. on RLS.
Feb. 22	From print. May be acted upon on or after March 24.
Feb. 21	Introduced. Read first time. To Com. on RLS, for assignment. To print.

### STATES WITH PRESCRIPTION MONITORING PROGRAMS January 2006

	STATE	PROGRAM TYPE	SCHEDULES COVERED	YEAR ENACTED
1	AL	Electronic	C II - V	2004
2	СО	Electronic	C II - V	2005
3	CA	Single-Copy Serialized Electronic	C II - V	2005
4	HI	Electronic	C II - IV	2002
5	ID	Electronic	C II - V	2001
6	IL	Electronic	CII	1999
7	IN	Electronic	C II - V	2004
8	KY	Electronic	C II - V	1998
9	ME	Electronic	C II - IV	2003
10	MA	Electronic	C II	1992
11	MI	Electronic	C II - V	2002
12	NC	Electronic	CII - V	2005
13	NM	Electronic	CII - IV	2004
14	NV	Electronic	C II - IV	1995
15	NY	Single-copy, serialized/Electronic (state-issued)	C II, Benzos	1998
16	ОН	Electronic	C II - V	2005
17	ОК	Electronic	C II	1990
18	RI	Electronic	C II, III	1997
19	TN	Electronic	C II - IV	2002
20	TX	Single-copy, serialized/Electronic (state-Issued)	CII	1997
21	UT	Electronic	C II - V	1995
22	VA	Electronic	C II - V	2002
23	WV	Electronic	C II - IV	1995

#### **Introduced by Senator Aanestad**

February 21, 2006

An act to amend Sections 11159.2, 11161, 11162.6, 11164, 11164.1, 11165, 11167, and 11167.5 of the Health and Safety Code, relating to controlled substances.

#### LEGISLATIVE COUNSEL'S DIGEST

SB 1366, as amended, Aanestad. Controlled substances.

Existing law regulates the prescription of controlled substances, as specified.

This bill would make technical, nonsubstantive changes to these provisions.

Existing law requires an authorized prescriber to write prescriptions for controlled substances on a specialized secured prescription form, and makes exceptions therefore.

This bill would remove the requirement that authorized persons write prescriptions for controlled substances on a specialized secured prescription form and delete the exceptions therefore.

Existing law allows a court to require a prescriber to turn over his or her specialized secured prescription forms for controlled substances when the prescriber is charged with a specified felony offense.

This bill would allow the court to issue an order prohibiting the prescriber from prescribing controlled substances when the prescriber is charged with a specified felony offense. Because a violation of this requirement would be a crime, the bill would impose a state-mandated local program.

SB 1366 -2-

Existing law makes it a crime to counterfeit a secured controlled substance prescription form.

This bill would repeal that crime.

10

11

12

13

14

15

16 17

18

19 20

21

22

The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.

This bill would provide that no reimbursement is required by this act for a specified reason.

Vote: majority. Appropriation: no. Fiscal committee: no-yes. State-mandated local program: no-yes.

The people of the State of California do enact as follows:

- SECTION 1. Section 11159.2 of the Health and Safety Code is amended to read:
- 3 11159.2. (a) Notwithstanding any other provision of law, a 4 prescription for a controlled substance for use by a patient who 5 has a terminal illness may be written on a prescription form that 6 does not meet the requirements of Section 11162.1 if the 7 prescription meets the following requirements:
- 8 (1) Contain the information specified in subdivision (a) of 9 Section 11164.
  - (2) Indicate that the prescriber has certified that the patient is terminally ill by the words "11159.2 exemption."
  - (b) A pharmacist may fill a prescription pursuant to this section when there is a technical error in the certification required by paragraph (2) of subdivision (a), provided that he or she has personal knowledge of the patient's terminal illness, and subsequently returns the prescription to the prescriber for correction within 72 hours.
  - (c) For purposes of this section, "terminally ill" means a patient who meets all of the following conditions:
  - (1) In the reasonable medical judgment of the prescribing physician, the patient has been determined to be suffering from an illness that is incurable and irreversible.
- 23 (2) In the reasonable medical judgment of the prescribing physician, the patient's illness will, if the illness takes its normal course, bring about the death of the patient within a period of one year.

-3- SB 1366

(3) The patient's treatment by the physician prescribing a controlled substance pursuant to this section primarily is for the control of pain, symptom management, or both, rather than for cure of the illness.

- SECTION 1. Section 11159.2 of the Health and Safety Code is repealed.
- 11159.2. (a) Notwithstanding any other provision of law, a prescription for a controlled substance for use by a patient who has a terminal illness may be written on a prescription form that does not meet the requirements of Section 11162.1 if the prescription meets the following requirements:
- (1) Contain the information specified in subdivision (a) of Section 11164.
- (2) Indicate that the prescriber has certified that the patient is terminally ill by the words "11159.2 exemption."
- (b) A pharmacist may fill a prescription pursuant to this section when there is a technical error in the certification required by paragraph (2) of subdivision (a), provided that he or she has personal knowledge of the patient's terminal illness, and subsequently returns the prescription to the prescriber for correction within 72 hours.
- (c) For purposes of this section, "terminally ill" means a patient who meets all of the following conditions:
- (1) In the reasonable medical judgment of the prescribing physician, the patient has been determined to be suffering from an illness that is incurable and irreversible.
- (2) In the reasonable medical judgment of the prescribing physician, the patient's illness will, if the illness takes its normal course, bring about the death of the patient within a period of one year.
- (3) The patient's treatment by the physician prescribing a controlled substance pursuant to this section primarily is for the control of pain, symptom management, or both, rather than for eure of the illness.
  - (d) This section shall become operative on July 1, 2004.
- SEC. 2. Section 11161 of the Health and Safety Code is amended to read:
- 38 11161. (a) When a practitioner is named in a warrant of arrest or is charged in an accusatory pleading with a felony violation of Section 11153, 11154, 11156, 11157, 11170, 11173,

SB 1366 —4—

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

3435

36

37

38

39

40

11350, 11351, 11352, 11353, 11353.5, 11377, 11378, 11378.5, . 1 11379, 11379.5, or 11379.6, the court in which the accusatory pleading is filed or the magistrate who issued the warrant of arrest shall, upon the motion of a law enforcement agency which 5 is supported by reasonable cause, issue an order-which requires 6 the practitioner to surrender to the clerk of the court all controlled 7 substance prescription forms in the practitioner's possession at a time set in the order and which prohibits the practitioner from 9 obtaining, ordering, or using any additional prescription forms. 10 prohibiting the practitioner from prescribing controlled substances. The law enforcement agency obtaining the order 11 12 shall notify the Department of Justice of this order. Except as 13 provided in subdivisions (b) and (e) of this section, the order 14 shall remain in effect until further order of the court. Any 15 practitioner possessing prescription forms who prescribes 16 controlled substances in violation of the order is guilty of a 17 misdemeanor.

- (b) The order provided by subdivision (a) shall be vacated if the court or magistrate finds that the underlying violation or violations are not supported by reasonable cause at a hearing held within two court days after the practitioner files and personally serves upon the prosecuting attorney and the law enforcement agency that obtained the order, a notice of motion to vacate the order with any affidavits on which the practitioner relies. At the hearing, the burden of proof, by a preponderance of the evidence, is on the prosecution. Evidence presented at the hearing shall be limited to the warrant of arrest with supporting affidavits, the motion to-require prohibit the defendant-to-surrender controlled substance prescription forms and to prohibit the defendant from obtaining, ordering, or using controlled substance prescription forms, with from prescribing controlled substances with supporting affidavits, the sworn complaint together with any documents or reports incorporated by reference thereto which, if based on information and belief, state the basis for the information, or any other documents of similar reliability as well as affidavits and counter affidavits submitted by the prosecution and defense. Granting of the motion to vacate the order is no bar to prosecution of the alleged violation or violations.
- (c) The defendant may elect to challenge the order issued under subdivision (a) at the preliminary examination. At that

\_5\_ SB 1366

hearing, the evidence shall be limited to that set forth in subdivision (b) and any other evidence otherwise admissible at the preliminary examination.

- (d) If the practitioner has not moved to vacate the order issued under subdivision (a) by the time of the preliminary examination and he or she is held to answer on the underlying violation or violations, the practitioner shall be precluded from afterwards moving to vacate the order. If the defendant is not held to answer on the underlying charge or charges at the conclusion of the preliminary examination, the order issued under subdivision (a) shall be vacated.
- (e) Notwithstanding subdivision (d), any practitioner who is diverted pursuant to Chapter 2.5 (commencing with Section 1000) of Title 7 of Part 2 of the Penal Code may file a motion to vacate the order issued under subdivision (a).
- SEC. 3. Section 11161.5 of the Health and Safety Code is repealed.
  - 11161.5. (a) Prescription forms for controlled substance prescriptions shall be obtained from security printers approved by the Department of Justice.
  - (b) The department may approve security printer applications after the applicant has provided the following information:
    - (1) Name, address, and telephone number of the applicant.
  - (2) Policies and procedures of the applicant for verifying the identity of the prescriber ordering controlled substance prescription forms.
  - (3) Policies and procedures of the applicant for verifying delivery of controlled substance prescription forms to prescribers.
  - (4) (A) The location, names, and titles of the applicant's agent for service of process in this state; all principal corporate officers, if any; and all managing general partners, if any.
  - (B) A report containing this information shall be made on an annual basis and within 30 days after any change of office, principal corporate officers, or managing general partner.
- (5) (A) A signed statement indicating whether the applicant, principal corporate officers, or managing general partners have ever been convicted of, or pled no contest to, a violation of any law of a foreign country, the United States, or any state, or of any local ordinance.

SB 1366 -6-

(B) The department shall provide the applicant with the means and direction to provide fingerprints and related information, in a manner specified by the department, for the purpose of completing state, federal, or foreign criminal background checks.

(C) Any applicant described in subdivision (b) shall submit his

- (C) Any applicant described in subdivision (b) shall submit his or her fingerprint images and related information to the department, for the purpose of the department obtaining information as to the existence and nature of a record of state, federal, or foreign level convictions and state, federal, or foreign level arrests for which the department establishes that the applicant was released on bail or on his or her own recognizance pending trial, as described in subdivision (I) of Section 11105 of the Penal Code. Requests for federal level criminal offender record information received by the department pursuant to this section shall be forwarded to the Federal Bureau of Investigation by the department.
- (D) The department shall assess against each applicant a fee determined by the department to be sufficient to cover all processing, maintenance, and investigative costs generated from or associated with completing state, federal, or foreign background checks pursuant to this section with respect to that applicant; the fee shall be paid by the applicant at the time he or she submits fingerprints and related information to the department.
- (E) The department shall retain fingerprint impressions and related information for subsequent arrest notification pursuant to Section 11105.2 of the Penal Code for all applicants.
- (e) The department may, within 60 calendar days of receipt of the application from the applicant, deny the security printer application.
- (d) The department may deny a security printer application on any of the following grounds:
- (1) The applicant, any individual owner, partner, corporate officer, manager, agent, representative, employee, or subcontractor for the applicant, who has direct access, management, or control of controlled substance prescription forms, has been convicted of a crime. A conviction within the meaning of this paragraph means a plea or verdict of guilty or a conviction following a plea of nolo contendere. Any action which a board is permitted to take following the establishment of

\_7\_ SB 1366

a conviction may be taken when the time for appeal has clapsed, the judgment of conviction has been affirmed on appeal, or when an order granting probation is made suspending the imposition of sentence, irrespective of a subsequent order under the provisions of Section 1203.4 of the Penal Code.

- (2) The applicant committed any act involving dishonesty, fraud, or deceit with the intent to substantially benefit himself, herself, or another, or substantially injure another.
- (3) The applicant committed any act that would constitute a violation of this division.
- (4) The applicant knowingly made a false statement of fact required to be revealed in the application to produce controlled substance prescription forms.
- (5) The department determines that the applicant failed to demonstrate adequate security procedures relating to the production and distribution of controlled substance prescription forms.
- (6) The department determines that the applicant has submitted an incomplete application.
- (7) As a condition for its approval as a security printer, an applicant shall authorize the Department of Justice to make any examination of the books and records of the applicant, or to visit and inspect the applicant during business hours, to the extent deemed necessary by the board or department to properly enforce this section.
- (e) An approved applicant shall submit an exemplar of a controlled substance prescription form, with all security features, to the Department of Justice within 30 days of initial production.
- (f) The department shall maintain a list of approved security printers and the department shall make this information available to prescribers and other appropriate government agencies, including the Board of Pharmacy.
- (g) Before printing any controlled substance prescription forms, a security printer shall verify with the appropriate licensing board that the prescriber possesses a license and current prescribing privileges which permits the prescribing of controlled substances.
- (h) Controlled substance prescription forms shall be provided directly to the prescriber either in person, by certified mail, or by

<u> 8 </u> **SB 1366** 

1

3 4

5 6

7

8

9

10

11

12 13

14

15

16

17

18

19

20

21

22

23

24

25

26 27

28

29

30

35

36

a means that requires a signature signifying receipt of the package and provision of that signature to the security printer.

- (i) Security printers shall retain ordering and delivery records in a readily retrievable manner for individual prescribers for three
- (i) Security printers shall produce ordering and delivery records upon request by an authorized officer of the law as defined in Section 4017 of the Business and Professions Code.
- (k) (1) The department may revoke its approval of a security printer for a violation of this division or action that would permit a denial pursuant to subdivision (d) of this section.
- (2) When the department revokes its approval, it shall notify the appropriate licensing boards and remove the security printer from the list of approved security printers.
- SEC. 4. Section 11161.7 of the Health and Safety Code is amended to read:
- 11161.7. (a) When a prescriber's authority to prescribe controlled substances is restricted by civil, criminal, or administrative action, or by an order of the court issued pursuant to Section 11161, the law enforcement agency or licensing board that sought the restrictions shall provide the name, category of licensure, license number, and the nature of the restrictions imposed on the prescriber to-security printers, the Department of Justice, and the Board of Pharmacy.
- The Board of Pharmacy shall make available the information required by subdivision (a) to pharmacies and security printers to prevent the dispensing of controlled substance prescriptions issued by the prescriber and the ordering of additional controlled substance prescription forms by the restricted prescriber.
- 31 SEC. 5. Section 11162.1 of the Health and Safety Code is 32 repealed.
- 11162.1. (a) The prescription forms for controlled substances 33 34 shall be printed with the following features:
- (1) A latent, repetitive "void" pattern shall be printed across the entire front of the prescription blank; if a prescription is seanned or photocopied, the word "void" shall appear in a pattern 37 across the entire front of the prescription.

**SB 1366** 

- (2) A watermark shall be printed on the backside of the 1 prescription blank; the watermark shall consist of the words 3 "California Security Prescription."
- 4 (3) A chemical void protection that prevents alteration by 5 chemical washing.
  - (4) A feature printed in thermo-chromic ink.
  - (5) An area of opaque writing so that the writing disappears if the prescription is lightened.
- (6) A description of the security features included on each prescription form. 10
- (7) (A) Six quantity check off boxes shall be printed on the 11 12 form and the following quantities shall appear:
- 13 1 - 24

6

7

8

9

22

23

24

25 26

27

28

29 30

31

32

33

34 35

- 14 25-49
- <del>50-74</del> 15
- 16 75-100
- 17 101-150
- 18 151 and over.
- 19 (B) In conjunction with the quantity boxes, a space shall be 20 provided to designate the units referenced in the quantity boxes 21 when the drug is not in tablet or capsule form.
  - (8) Prescription blanks shall contain a statement printed on the bottom of the prescription blank that the "Prescription is void if the number of drugs prescribed is not noted."
  - (9) The preprinted name, category of licensure, license number, federal controlled substance registration number of the prescribing practitioner.
  - (10) A check box indicating the prescriber's order not to
  - (11) An identifying number assigned to the approved security printer by the Department of Justice.
  - (12) (A) A check box by the name of each prescriber when a prescription form lists multiple prescribers.
  - (B) Each prescriber who signs the prescription form shall identify himself or herself as the prescriber by checking the box by their name.
- 37 (b) Each batch of controlled substance prescription forms shall have the lot number printed on the form and each form within that batch shall be numbered sequentially beginning with the 39 40 numeral one.

SB 1366 —10—

1 2

(c) (1) A prescriber designated by a licensed health care facility, a clinic specified in Section 1200, or a clinic specified in subdivision (a) of Section 1206 that has 25 or more physicians or surgeons may order controlled substance prescription forms for use by prescribers when treating patients in that facility without the information required in paragraph (9) of subdivision (a) or paragraph (3) of this subdivision.

- (2) Forms ordered pursuant to this subdivision shall have the name, category of licensure, license number, and federal controlled substance registration number of the designated prescriber and the name, address, category of licensure, and license number of the licensed health care facility the clinic specified in Section 1200, or the clinic specified in subdivision (a) of Section 1206 that has 25 or more physicians or surgeons preprinted on the form.
- (3) Forms ordered pursuant to this section shall not be valid prescriptions without the name, eategory of licensure, license number, and federal controlled substance registration number of the prescriber on the form.
- (4) (A) Except as provided in subparagraph (B), the designated prescriber shall maintain a record of the prescribers to whom the controlled substance prescription forms are issued, that shall include the name, category of licensure, license number, federal controlled substance registration number, and the quantity of controlled substance prescription forms issued to each prescriber and be maintained in the health facility for three years.
- (B) Forms ordered pursuant to this subdivision that are printed by a computerized prescription generation system shall not be subject to the requirements set forth in subparagraph (A) or paragraph (7) of subdivision (a). Forms printed pursuant to this subdivision that are printed by a computerized prescription generation system may contain the prescriber's name, category of professional licensure, license number, federal controlled substance registration number, and the date of the prescription.
- (d) This section shall become operative on July 1, 2004. SEC. 3.
- 37 SEC. 6. Section 11162.6 of the Health and Safety Code is amended to read:
- 39 11162.6. (a) Every person who counterfeits a controlled 40 substance prescription form shall be guilty of a misdemeanor

—11— SB 1366

punishable by imprisonment in a county jail for not more than one year, by a fine not exceeding one thousand dollars (\$1,000), or by both that imprisonment and fine.

- (b) Every person who knowingly possesses a counterfeited controlled substance prescription form shall be guilty of a misdemeanor punishable by imprisonment in a county jail not exceeding six months, by a fine not exceeding one thousand dollars (\$1,000), or by both that imprisonment and fine.
- (e)—Every person who attempts to obtain or obtains a controlled substance prescription form under false pretenses shall be guilty of a misdemeanor punishable by imprisonment in a county jail not exceeding six months, by a fine not exceeding one thousand dollars (\$1,000), or by both that imprisonment and fine.
- (d) Every person who fraudulently produces controlled substance prescription forms shall be guilty of a misdemeanor punishable by imprisonment in a county jail not exceeding six months, by a fine not exceeding one thousand dollars (\$1,000), or by both that imprisonment and fine.

SEC. 4.

- SEC. 7. Section 11164 of the Health and Safety Code is amended to read:
- 11164. Except as provided in Section 11167, no person shall prescribe a controlled substance, nor shall any person fill, compound, or dispense a prescription for a controlled substance, unless it complies with the requirements of this section.
- (a) Each prescription for a controlled substance classified in Schedule II, III, IV, or V, except as authorized by subdivision (b), shall be made on a controlled substance prescription form as specified in Section 11162.1 and shall meet the following requirements:
- (1) The prescription shall be signed and dated by the prescriber in ink and shall contain the prescriber's address and telephone number; the name of the person for whom the controlled substance is prescribed; and the name, quantity, strength, and directions for use of the controlled substance prescribed.
- (2) The prescription shall also contain the address of the person for whom the controlled substance is prescribed. If the prescriber does not specify this address on the prescription, the pharmacist filling the prescription or an employee acting under

SB 1366 -12-

the direction of the pharmacist shall write or type the address on the prescription or maintain this information in a readily retrievable form in the pharmacy.

- (b) (1) Notwithstanding paragraph (1) of subdivision (a) of Section 11162.1, any controlled substance classified in Schedule III, IV, or V may be dispensed upon an oral or electronically transmitted prescription, which shall be produced in hard copy form and signed and dated by the pharmacist filling the prescription or by any other person expressly authorized by provisions of the Business and Professions Code. Any person who transmits, maintains, or receives any electronically transmitted prescription shall ensure the security, integrity, authority, and confidentiality of the prescription.
- (2) The date of issue of the prescription and all the information required for a written prescription by subdivision (a) shall be included in the written record of the prescription; the pharmacist need not include the address, telephone number, license classification, or federal registry number of the prescriber or the address of the patient on the hard copy, if that information is readily retrievable in the pharmacy.
- (3) Pursuant to an authorization of the prescriber, any agent of the prescriber on behalf of the prescriber may orally or electronically transmit a prescription for a controlled substance classified in Schedule III, IV, or V, if in these cases the written record of the prescription required by this subdivision specifies the name of the agent of the prescriber transmitting the prescription.
- 28 (c) The use of commonly used abbreviations shall not 29 invalidate an otherwise valid prescription.
  - (d) Notwithstanding any provision of subdivisions (a) and (b), prescriptions for a controlled substance classified in Schedule V may be for more than one person in the same family with the same medical need.

SEC. 5.

- 35 SEC. 8. Section 11164.1 of the Health and Safety Code is amended to read:
- 37 11164.1. (a) (1) Notwithstanding any other provision of 38 law, a prescription for a controlled substance issued by a 39 prescriber in another state for delivery to a patient in another 40 state may be dispensed by a California pharmacy, if the

-13 - SB 1366

prescription conforms with the requirements for controlled substance prescriptions in the state in which the controlled substance was prescribed.

- (2) All prescriptions for Schedule II and Schedule III controlled substances dispensed pursuant to this subdivision shall be reported by the dispensing pharmacy to the Department of Justice in the manner prescribed by subdivision (d) of Section 11165.
- (b) Pharmacies may dispense prescriptions for Schedule III, Schedule IV, and Schedule V controlled substances from out-of-state prescribers pursuant to Section 4005 of the Business and Professions Code and Section 1717 of Title 16 of the California Code of Regulations.

SEC. 6.

2

4

5

8

9

10

11

12 13

14

15

- SEC. 9. Section 11165 of the Health and Safety Code is amended to read:
- 17 (a) To assist law enforcement and regulatory 11165. 18 agencies in their efforts to control the diversion and resultant 19 abuse of Schedule II and Schedule III controlled substances, and 20 for statistical analysis, education, and research, the Department 21 of Justice shall, contingent upon the availability of adequate 22 funds from the Contingent Fund of the Medical Board of 23 California, the Pharmacy Board Contingent Fund, the State 24 Dentistry Fund, the Board of Registered Nursing Fund, and the 25 Osteopathic Medical Board of California Contingent Fund, 26 maintain the Controlled Substance Utilization Review and 27 Evaluation System (CURES) for the electronic monitoring of the 28 prescribing and dispensing of Schedule II and Schedule III 29 controlled substances by all practitioners authorized to prescribe 30 or dispense these controlled substances.
- 31 (b) The reporting of Schedule III controlled substance 32 prescriptions to CURES shall be contingent upon the availability of adequate funds from the Department of Justice. The 33 Department of Justice may seek and use grant funds to pay the 34 35 costs incurred from the reporting of controlled substance prescriptions to CURES. Funds shall not be appropriated from 37 the Contingent Fund of the Medical Board of California, the 38 Pharmacy Board Contingent Fund, the State Dentistry Fund, the 39 Board of Registered Nursing Fund, the Naturopathic Doctor's 40 Fund, or the Osteopathic Medical Board of California Contingent

SB 1366 — 14 —

Fund to pay the costs of reporting Schedule III controlled substance prescriptions to CURES.

- (c) CURES shall operate under existing provisions of law to 4 safeguard the privacy and confidentiality of patients. Data obtained from CURES shall only be provided to appropriate state, local, and federal persons or public agencies for disciplinary, civil, or criminal purposes and to other agencies or entities, as determined by the Department of Justice, for the purpose of educating practitioners and others in lieu of 10 disciplinary, civil, or criminal actions. Data may be provided to 11 public or private entities, as approved by the Department of 12 Justice, for educational, peer review, statistical, or research purposes, provided that patient information, including any 13 information that may identify the patient, is not compromised. 15 Further, data disclosed to any individual or agency as described in this subdivision shall not be disclosed, sold, or transferred to 16 17 any third party. 18
  - (d) For each prescription for a Schedule II or Schedule III controlled substance, the dispensing pharmacy shall provide the following information to the Department of Justice in a frequency and format specified by the Department of Justice:
    - (1) Full name, address, gender, and date of birth of the patient.
  - (2) The prescriber's category of licensure and license number; federal controlled substance registration number; and the state medical license number of any prescriber using the federal controlled substance registration number of a government-exempt facility.
- 28 (3) Pharmacy prescription number, license number, and 29 federal controlled substance registration number.
- 30 (4) NDC (National Drug Code) number of the controlled substance dispensed.
  - (5) Quantity of the controlled substance dispensed.
    - (6) ICD-9 (diagnosis code), if available.
  - (7) Date of issue of the prescription.
- 35 (8) Date of dispensing of the prescription.
- 36 SEC. 7.

19

20 21

22

23

24

25

26

27

32 33

- 37 SEC. 10. Section 11167 of the Health and Safety Code is amended to read:
- 39 11167. Notwithstanding subdivision (a) of Section 11164, in 40 an emergency where failure to issue a prescription may result in

-15- SB 1366

loss of life or intense suffering, an order for a controlled substance may be dispensed on an oral order, an electronic data transmission order, or a written order not made on a controlled substance form as specified in Section 11162.1, subject to all of the following requirements:

- (a) The order contains all information required by subdivision (a) of Section 11164.
- (b) Any written order is signed and dated by the prescriber in ink, and the pharmacy reduces any oral or electronic data transmission order to hard copy form prior to dispensing the controlled substance.
- (c) The prescriber provides a written prescription—on—a controlled substance prescription form that meets the requirements of Section 11162.1, by the seventh day following the transmission of the initial order; a postmark by the seventh day following transmission of the initial order shall constitute compliance.
- (d) If the prescriber fails to comply with subdivision (c), the pharmacy shall so notify the Bureau of Narcotic Enforcement in writing within 144 hours of the prescriber's failure to do so and shall make and retain a hard copy, readily retrievable record of the prescription, including the date and method of notification of the Bureau of Narcotic Enforcement.

SEC. 8.

- SEC. 11. Section 11167.5 of the Health and Safety Code is amended to read:
- 11167.5. (a) An order for a controlled substance classified in Schedule II for a patient of a licensed skilled nursing facility, a licensed intermediate care facility, a licensed home health agency, or a licensed hospice may be dispensed upon an oral or electronically transmitted prescription. If the prescription is transmitted orally, the pharmacist shall, prior to filling the prescription, reduce the prescription to writing in ink in the handwriting of the pharmacist on a form developed by the pharmacy for this purpose. If the prescription is transmitted electronically, the pharmacist shall, prior to filling the prescription, produce, sign, and date a hard copy prescription. The prescriptions shall contain the date the prescription was orally or electronically transmitted by the prescriber, the name of the person for whom the prescription was authorized, the name

**— 16 — SB 1366** 

19

21

25

1 and address of the licensed skilled nursing facility, licensed intermediate care facility, licensed home health agency, or licensed hospice in which that person is a patient, the name and quantity of the controlled substance prescribed, the directions for use, and the name, address, category of professional licensure, 5 license number, and federal controlled substance registration number of the prescriber. The original shall be properly endorsed by the pharmacist with the pharmacy's state license number, the name and address of the pharmacy, and the signature of the person who received the controlled substances for the licensed 10 skilled nursing facility, licensed intermediate care facility, 11 licensed home health agency, or licensed hospice. A licensed 12 skilled nursing facility, a licensed intermediate care facility, a 13 licensed home health agency, or a licensed hospice shall forward 14 15 to the dispensing pharmacist a copy of any signed telephone 16 orders, chart orders, or related documentation substantiating each 17 oral or electronically transmitted prescription transaction under 18 this section.

SEC. 12. No reimbursement is required by this act pursuant 20 to Section 6 of Article XIII B of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new 22 23 crime or infraction, eliminates a crime or infraction, or changes 24 the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition 26 of a crime within the meaning of Section 6 of Article XIII B of the 27 California Constitution.